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1. INTRODUCTION 
1.1.  Staphylococcus aureus (S. aureus) 
1.1.1. Overview of S. aureus 
 
S. aureus was discovered in the 1880s (Ogston 1880, Ogston 1881, Ogston 1882a, Ogston 
1882b) and is a faculative pathogenic Gram-positive bacterium. Currently, S. aureus is one of 
the most virulent and common pathogens inside and outside hospitals and infections with S. 
aureus are associated with considerable morbidity and mortality (Laupland et al 2013, Tom et 
al 2014, van Hal et al 2012). 
 
Humans and other mammals are major reservoirs for S. aureus. Three out of ten people in the 
United States are asymptomatically colonized with S. aureus on their skin or mucous 
membranes, most commonly in the anterior nares (Gorwitz et al 2008). Some people are only 
intermittent carriers, and some carry the bacteria for longer periods. Nasal colonization with S. 
aureus increases the risk of developing serious infection by the same strain (von Eiff et al 
2001, Williams et al 1959), as when the bacterium is introduced into deeper tissues by cuts in 
the skin, in-dwelling catheters, aspiration, or surgery. Moreover, immune-deficient patients 
with advanced surgery, malignant diseases, prolonged stays in intensive care units and 
long-term care facilities and old patients are increasing since the beginning of the 21st century, 
which is another reason for S. aureus infections. 
 
Skin and soft tissue infection (SSTI) is the most common clinical manifestation of S. aureus 
disease (Hayward et al 2008, Lautz et al 2011), recent studies describe an increase in the 
incidence of SSTI in Australia and New Zealand over the past decade (O'Sullivan et al 2011, 
Vaska et al 2012, Williamson et al 2013, Williamson et al 2014). In addition to S. aureus 
SSTI, S. aureus also causes a spectrum of invasive infections, including osteomyelitis, 
necrotizing pneumonia, joint infections, endocarditis, sepsis, and death. In particular, S. 
aureus bacteremia is associated with considerable morbidity and mortality, with reported 
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global incidence rates varying between 14 and 41 per 100,000 population (El Atrouni et al 
2009, Laupland et al 2013), although it should be noted that differences in case ascertainment 
and study methodology limit comparisons between regions. 
 
1.1.2. Evolution of S. aureus 
In the pre-antibiotic era, prior to the introduction of penicillin for the treatment of S. aureus 
infections, the mortality rate of individuals with an S. aureus infection was about 80% 
(Skinner et al 1941). In 1929, Alexander Fleming reported his observations of the bactericidal 
effects of a fungal contaminant that produced penicillin, which can kill S. aureus on culture 
plates and is non-toxic to animals in enormous doses (Fleming 1929). Subsequently, with 
mass production of penicillin, the death rates from bacterial pneumonia and meningitis in 
World War II dramatically dropped, comparing to World War I (Neushul 1993).  
 
Alexander Fleming noted that the growth of E. coli and a number of other bacteria belonging 
to the colityphoid group was not inhibited by penicillin (Fleming 1929). Further work has 
been done to find the cause of the resistance of these organisms to the action of penicillin. In 
1940, an enzyme, which was called “penicillinase” and capable of hydrolyzing the active 
β-lactam ring in penicillin, was described in Escherichia coli (E. coli) (Abraham 1940). Soon 
thereafter, in 1944, penicillinase was extracted from penicillin resistant Staphylococci (Kirby 
1944). Later on, more and more penicillin-resistant S. aureus strains were observed in the 
hospital and community. Currently, 90 to 95% of all S. aureus strains are resistant to 
penicillin, with the plasmid encoded penicillinase readily transferable via transduction or 
conjugation. 
 
In 1961, 2 years after the introduction of methicillin, a penicillinase-resistant penicillin, the 
first strain of methicillin-resistant S. aureus (MRSA) was reported in a United Kingdom 
hospital due to the acquisition of the mecA gene (Eriksen 1961). This gene encodes for a 
penicillin-binding protein (PBP2a) which is expressed in the bacterial cell wall and which has 
a low affinity for β-lactam antibiotics. Thus, this group of antibiotics can’t disrupt the 
synthesis of the peptidoglycan layer of bacteria and is ineffective against bacteria expressing 
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this gene. As a consequence, S. aureus will survive. There is evidence that strains of 
methicillin-sensitive S. aureus (MSSA)  became methicillin resistant through the acquisition 
of the SCCmec element, probably from coagulase-negative staphylococcal strains, and that 
this has occurred on multiple occasions (Robinson et al 2004). The gene encoding meticillin 
resistance, mecA, is part of a larger genetic element known as the staphylococcal 
chromosomal cassette mec (SCCmec) (Ito et al 2001). The SCCmec element contains the 
mecA gene, chromosomal cassette recombinase (ccr) genes, mec regulatory genes and a 
junkyard region which contains non-essential components of SCCmec (Deurenberg et al 
2008). 
 
In recent years MRSA is now reported in about 60 to 70% of all S. aureus isolates found 
worldwide. There are now almost 100,000 cases of life threatening MRSA infections in the 
U.S. each year, evidences from the Centers for Disease Control and Prevention suggest with 
about 19,000 related deaths, more than the number of deaths from acquired immune 
deficiency syndrome (AIDS), which is induced by human immunodeficiency virus (HIV) 
(Klevens et al 2007). 
 
Glycopeptides, such as vancomycin, are the treatment of choice for infections due to MRSA. 
Unfortunately, up to now, three vancomycin-resistant MRSA isolates have been reported 
from the US since 2002 (Boyce et al 2005, Courvalin 2006, Weigel et al 2007). By far, the 
biggest threat in S. aureus is the spread of vancomycin-resistant MRSA isolates. Lack of 
previous or additional reports of vancomycin-resistant MRSA isolates might be because of 
lack of detection (several of those isolates had vancomycin intermediate susceptibility) or to 
lack of stability of the plasmid-mediated vancomycin-resistant determinants in S. aureus 
(Perichon et al 2004). However, a recent report indicates that a single plasmid transfer from 
vancomycin-resistant enterococci to MRSA may be sufficient for expression of resistance 
(Weigel et al 2007).  
 
Linezolid, quinupristin-dalfopristin, tigecycline, ceftopibrole and daptomycin are all available 
therapeutic options for treating vancomycin-resistant MRSA infections since they are all 
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active in vitro against those isolates. However, the clinical efficacy of the best antibiotic 
combinations remains to be determined using animal models of infection since we 
(fortunately) have not faced outbreaks with those isolates to this day. 
 
1.1.3. Typing methods for S. aureus 
For the first three decades after their appearance, MRSA strains typically have remained 
hospital associated MRSA (HA-MRSA). In addition, since the 1990s, in an unexpected 
epidemiological ‘move’, MRSA strains also began to appear in the community among people 
who had none of the usual risk factors for such infections. Such community acquired MRSA 
(CA-MRSA), characterized by the presence of the toxin Panton-Valentine leukocidin, spread 
worldwide, first in the community, but later on also in healthcare facilities. At this moment, 
the distinction between CA-MRSA and HA-MRSA is beginning to fade (Lowy 1998, Lowy 
2003). 
 
A thorough knowledge of the spread and the molecular evolution of MRSA is required to 
effective develop strategies to control the dissemination of MRSA. Therefore, several typing 
methods have been developed during the last decades. MRSA strains can be typed using both 
phenotypic and molecular methods. There are many phenotypic typing methods, including the 
use of colonial characteristics, biochemical reactions, antibiotic susceptibility pattern, 
susceptibility to various phages and toxin production. The most important molecular typing 
methods in current use comprise pulsed-field gel electrophoresis, multilocus sequence typing, 
SCCmec typing and spa locus typing (Aires de Sousa et al 2004). 
 
Pulsed-field gel electrophoresis (PFGE). As one of the earlier molecular methods, PFGE 
remains the most popular technique to differentiate MRSA isolates. In PFGE for S. aureus, 
the chromosomal DNA is digested with the restriction enzyme SmaI, and the obtained DNA 
fragments are separated by agarose gel electrophoresis in an electric field with an alternating 
voltage gradient. The resulting banding patterns are analyzed using a special software package 
(Tenover et al 1995). The advantage of this method is that it provides great discrimination 
between strains and is useful in the investigation of outbreaks by allowing differentiation of 
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unrelated strains. Disadvantages associated with the method relate principally to difficulties 
with inter-laboratory comparison of results. Thus reliable comparison of strains between 
regions and internationally is not always possible. 
 
Multilocus sequence typing (MLST). MLST is based on the sequence analysis of fragments 
of seven S. aureus housekeeping genes, i.e. arcC, aroE, glpF, gmk, pta, tpi and yqiL, each 
approximately 500-bp in length (Enright et al 2000). The DNA sequences are compared to 
those of previously identified alleles at each locus on the MLST online database 
(http://www.mlst.net). Each allele is given a number, and a string of seven numbers then 
represents the allelic profile designated sequence type (ST) of an isolate. The MLST scheme 
for S. aureus was developed in 2000 and the details of more than 1500 isolates are available at 
the S. aureus MLST website http://saureus.mlst.net (Enright 2006). The advantage of MLST 
is that the geographic source and clinical information on each isolate can be stored with its 
sequence online, making it useful for international and local surveillance purposes. 
Disadvantages associated with MLST are the economic and time-consuming costs of 
performing seven PCRs and 14 DNA-sequencing reactions per isolate. 
 
SCCmec typing. Seven major SCCmec types and their subtypes, which range in size from 20 
to 67 kb, are defined by combinations of different classes of mec and ccr genes (Chongtrakool 
et al 2006). The SCCmec gene cluster evolves rapidly and becomes another target for 
sequencing methods to differentiate MRSA strains. Unfortunately, a major disadvantage of 
such a method is that it is not feasible for routine applications, since the relative large number 
of PCR reactions that are needed to determine the structure of SCCmec are time consuming 
(Kondo et al 2007).  
 
Spa locus typing. Typing of a single locus zone in the polymorphic region X of S. aureus 
protein A (spa) has also become increasingly popular during recent years (Frenay et al 1996, 
Moodley et al 2006). The diversity of the spa gene, consisting mainly of a number of repeats 
of 24 bp in length, is attributed to point mutations, as well as to deletions and duplications of 
the repeats (Kahl et al 2005, Shopsin et al 1999). Spa typing is less expensive and 
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time-consuming than MLST and can be used to study both the molecular evolution as well as 
inter-hospital comparisons since it requires sequencing of one locus. 
 
In summary, although a lot of knowledge on the spread of MRSA clones has been gained in 
last decades, there are still a number of questions unanswered. Further investigations, 
addressing both basic research and performing epidemiological studies, are needed to 
understand completely the molecular evolution of S. aureus. 
 
1.2. Sepsis  
1.2.1. Overview of sepsis 
Sepsis is a very heterogeneous clinical syndrome broadly defined as the systemic host 
response to an infection. Indeed, sepsis can be initiated by any microorganism, whether it is 
bacterial, fungal, viral, parasitic, or by microbial products and toxins, and is then propagated 
by a complex network of inflammatory mediators and cellular dysfunction. 
 
In 1989, Roger Bone and colleagues proposed the term “sepsis syndrome” for the first time to 
define patients who have severe sepsis, by establishing a set of clinical parameters (Bone et al 
1989). Sepsis syndrome was defined as hypothermia (less than 96 ⁰F [35.5 ⁰C]) or 
hyperthermia (greater than 101 ⁰F [38.3 ⁰C])； tachycardia (greater than 90 beat/min); 
tachypnea (greater than 20 breath/min)； clinical evidence of an infection site； and the 
presence of at least one end-organ demonstrating inadequate perfusion or dysfunction 
expressed as poor or altered cerebral function, hypoxemia (PaO2 less than 100 mbar on room 
air), elevated plasma lactate， or oliguria (urine output less than 30 mL/h or 0.5 mL/kg body 
weight/h without corrective therapy) (Bone et al 1989). If untreated, the patient may develop 
systemic inflammatory response syndrome (SIRS), septic shock and multisystem organ 
failure (MSOF), which are the deadly forms of the disease. 
 
The most common sites of bacterial infection are the lungs, abdominal cavity, the skin, the 
urinary tract and primary infections of the blood stream. A microbiological diagnosis is made 
INTRODUCTION 
- 7 - 
in about half the cases; Gram-negative bacteria account for about 60% of cases, 
Gram-positive for the remainder (Alberti et al 2002, Angus et al 2001). 
 
Sepsis remains a significant problem in medical management, with an annual worldwide 
incidence of approximately 18 million cases with an associated 30-40% mortality rate (Blanco 
et al 2008, Karlsson et al 2007). In the U.S. alone, approximately 750,000 patients annually 
are diagnosed with sepsis, with a mortality rate ranging from 30% to 50% (Angus et al 2001). 
Most patients with sepsis are admitted to intensive care units and are on mechanical 
ventilation. The U.S. Center for Disease Control and Prevention indicates that sepsis is one of 
the top ten leading causes of death in the U.S., and estimates the annual costs for the treatment 
of patients with sepsis are estimated to exceed $17 billion (Angus et al 2001). Sepsis may be 
responsible for a majority of the mortality associated with significant public health concerns 
such as malaria, tuberculosis, HIV/AIDS and others. What’s more, the incidence of sepsis 
increases annually probably mainly due to an increase in the number of immunocompromised 
patients, increase in antibiotic resistance and the aging population. 
 
Unfortunately, very few new treatments have been introduced over the past several decades 
although many people are working in the field. Current management of septic patients is 
predominantly non-specific, relying on a range of interventions such as intravenous fluids and 
medications, antibiotics, mechanical ventilation, nutritional support and corticosteroid therapy. 
Therefore, there is an urgent need for new effective treatments for sepsis. 
 
1.2.2. Sepsis pathogenesis 
Sepsis develops when the host response to a pathogen or a microbial toxin is accelerated to an 
inappropriate degree. The immune system relies on a process of molecular pattern recognition 
to determine the appropriate immunologic response to a foreign protein. These bacterial 
motifs, which are recognized by the innate immune system, have been named 
pathogen-associated molecular patterns (PAMPs) or microorganism-associated molecular 
patterns (Janeway et al 1998). In Gram-negative bacteria, lipopolysaccharide (LPS; known 
also as endotoxin) correlates with the ability to activate host cell membranes. In Gram- 
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positive bacteria, identified structural components in the bacteria cell wall account for their 
biological activity since there is no endotoxin in these type of bacteria (Majcherczyk et al 
1999, Morath et al 2001). However, Gram-positive bacteria can also produce potent exotoxins, 
which exhibit the properties of super antigens and cause massive T-cell activation and release 
of pro-inflammatory lymphokines, suggesting a plausible role for these toxins as a cause of 
the profound shock that is seen in patients with toxic shock (Lavoie et al 1999). 
 
PAMP’s as well as other danger-associated molecular pattern (DAMP) molecules will bind to 
their receptors in the host cell membrane and begin a process of intracellular signaling and 
cellular activation: On one hand, the mechanisms involve widespread fibrin deposition 
causing microvascular occlusion, the development of tissue exudates further compromising 
adequate oxygenation, and disorders of microvascular homeostasis resulting from the 
elaboration of vasoactive substances such as platelet-activating factor (PAF), histamine and 
prostanoids (Anderson et al 1991). On the other hand, cellular infiltrates, particularly 
neutrophils, damage tissue directly by releasing lysosomal enzymes and superoxide-derived 
free radicals. TNF-α and other cytokines increase the expression of the inducible nitric oxide 
synthase and increased production of nitric oxide causes further vascular instability (Azevedo 
et al 2006) and may also contribute to the direct myocardial depression that occurs in sepsis 
(Landry et al 2001). Microvascular occlusion and vascular instability results in coagulopathy, 
fever, vasodilation and capillary leak, ultimately sepsis and multiple organ failure (Cohen 
2002) (Figure 1.2.2.1.). 
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Figure 1.2.2.1. Pathogenetic networks in septic shock 
 
Lipopolysaccharide (LPS) and other microbial components simultaneously activate multiple parallel 
cascades that contribute to the pathophysiology of adult respiratory distress syndrome (ARDS) and 
septic shock. The combination of poor myocardial contractility, impaired peripheral vascular tone and 
microvascular occlusion results in tissue hypoperfusion and inadequate oxygenation, and finally 
multiple organ failure (Cohen 2002). 
 
During a very long time, the prevailing concept of the pathogenesis of sepsis was that 
mortality is the consequence of an uncontrolled hyper-inflammatory response of the host. The 
disappointing results of nearly 40 years of anti-inflammatory strategies and the development 
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of animal models that more closely mimic clinical sepsis have led to the reconsideration of 
the pathophysiology of sepsis. Sepsis is now considered a misbalance between 
pro-inflammatory reactions (designed to kill invading pathogens but at the same time 
responsible for tissue damage) and anti-inflammatory responses (designed to limit excessive 
inflammation, but at the same time making the host more vulnerable for secondary infections) 
(Anas et al 2010) (Figure 1.2.2.2.).  
 
 
Figure 1.2.2.2. Important components of the host response to sepsis    
 
The interaction between pathogens and the host is mediated initially via an interaction between 
PAMPs (pathogen associated molecular pathogens) and TLRs (Toll-like receptors). The resulting 
innate response of immune cells can result in a balanced reaction leading to pathogen elimination and 
tissue recovery or an unbalanced reaction that on the one hand can lead to exaggerated inflammation 
and tissue injury and on the other hand to immune suppression caused by immune cell apoptosis (Anas 
et al 2010).    
In addition, new players have been described in the field of vascular dysfunction, such as 
platelet-derived microparticles, which are associated with apoptosis of vascular cells and 
cardiac failure (Azevedo et al 2007). However, the correlation of these pathways to outcome 
is so far poorly understood. 
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1.2.3. Mechanisms of acute lung injury (ALI) and acute respiratory distress syndrome 
(ARDS) 
Currently, the incidence of ALI and ARDS in the USA has been reported to be 79 and 59 per 
100,000 people per year, respectively (Bernard et al 1994, Herridge et al 2005, Peek et al 
2006, Rubenfeld et al 2005, Wheeler et al 2007). Based on the growth of the population, the 
incidence will likely double in the next 25 years (Rubenfeld et al 2005).  
 
The highest incidence of ALI is seen during sepsis, with approximately 25% of all ARDS 
cases stemming from severe sepsis (Brun-Buisson et al 2004) and 42.8% of sepsis was 
pneumonia (Blanco et al 2008). Moreover, ALI/ARDS are associated with a lethality of 
approximately 40%, accounting for around 75,000 deaths per year in the USA (Rubenfeld et 
al 2005, Wheeler et al 2007). 
 
ALI/ARDS was first described in 1967 (Ashbaugh et al 1967) and a large body of research 
has been ongoing in order to understand ALI/ARDS and to improve the clinical outcomes of 
this entity. ALI/ARDS is a clinical syndrome, characterized by the acute onset of severe 
hypoxemia with diffuse bilateral infiltrates in the chest radiograph and without evidence of 
left atrial hypertension. The difference between both entities is the degree of hypoxemia. In 
ALI, the ratio of arterial oxygen tension (PaO2) to the fraction of inspired oxygen (FiO2) is ≤
300, while in ARDS it is ≤200 (Bernard et al 1994). 
 
The pathophysiology of ALI/ARDS is not completely understood. Initially, a direct 
pulmonary or indirect extrapulmonary insult is believed to cause a proliferation of 
inflammatory mediators that promote neutrophil accumulation in the microcirculation of the 
lung. These neutrophils activate and migrate in large numbers across the vascular endothelial 
and alveolar epithelial surfaces, releasing proteases, cytokines, and reactive oxygen species. 
This migration and mediator release lead to pathologic vascular permeability, gaps in the 
alveolar epithelial barrier, and necrosis of type I and II alveolar cells. This, in turn, leads to 
the pulmonary edema, hyaline membrane formation, and loss of surfactant that decrease 
pulmonary compliance and make air exchange difficult. Subsequent infiltration of fibroblasts 
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can result in collagen deposition, fibrosis, and further progression of the disease (Matthay et 
al 2003, Matthay et al 2005, Ware et al 2000). 
 
Increased permeability of microvascular barriers, resulting in extravascular accumulation of 
protein-rich edema fluid, is a cardinal feature of acute inflammation and a central 
pathophysiologic mechanism in ALI and ARDS (Figure 1.2.3.) (Bachofen et al 1977, 
Matthay et al 2003, Ware et al 2000).  
 
Neutrophils are proposed to have an important role in mediating ALI. When recruited to a site 
of infection/inflammation, they exert a variety of beneficial functions (phagocytosis, 
production of reactive oxygen species and nitric oxide species, and degranulation of lytic 
enzymes) that, when well regulated, enable clearance of the invading pathogen. However, it is 
also hypothesized that the recruitment of activated PMNs may be potentially harmful when 
these same functions are dysregulated and directed at otherwise normal host tissue, 
culminating in injury and organ damage.  
 
 
Figure 1.2.3. Mechanism of lung edema 
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(A) Disrupted alveolar barrier function, resulting in increased permeability to water, proteins, and 
other solutes, is a hallmark of clinical and experimental ALI. Intra-alveolar accumulation of 
neutrophils, other leukocytes, erythrocytes and inflammatory mediators is also associated with altered 
endothelial and epithelial barrier function. (B) Disruption of VE-cadherin bonds is a central 
mechanism of altered endothelial barrier function in experimental ALI and in models of sepsis and 
systemic vascular destabilization. Disruption of VE-cadherin bonds also facilitates transendothelial 
migration of leukocytes and, in some studies, is associated with accumulation of leukocytes and 
platelets in microvessels (Matthay 2003).  
 
1.2.4. ALI/ARDS therapy 
Despite the importance of ALI/ARDS healthcare issue, very few new treatments have been 
introduced over the past three decades, and the mortality and morbidity rates of ALI/ARDS 
-related conditions remains high. Current management of ALI/ARDS patients is 
predominantly non-specific, relying on a range of interventions such as intravenous fluids and 
medications, antibiotics, mechanical ventilation, nutritional support, corticosteroid therapy, 
and prevention of stress ulcers and venous thromboembolism (Adhikari et al 2004, Briel et al 
2010, Dellinger et al 2008, Geerts et al 2008, Lin et al 2010, National Heart et al 2006, Peter 
et al 2008, Petrucci et al 2013). 
 
Despite the large amount of research elucidating the molecular mechanisms underlying ALI/ 
ARDS, the investigation of pharmacologic therapies has led almost exclusively to negative 
results, often in contrast to very promising results in animal studies. Although some animal 
studies support the potential efficacy of anti-inflammatory therapies for decreasing lung 
injury, clinical trials have not demonstrated a convincing reduction in mortality using 
granulocyte-macrophage colony stimulating factor (GM-CSF) or glucocorticoids, antioxidants, 
or anticytokine therapies that were tested in patients with sepsis (Bernard et al 1987, Bernard 
et al 1997, Meduri et al 1998, Meduri et al 2007, Paine et al 2012, Steinberg et al 2006). 
Although pulmonary hypertension and lung vascular injury are important features of ALI and 
ARDS, vasodilator therapies including prostaglandin E1 and nitric oxide have not reduced 
mortality (Abraham et al 1999, Taylor et al 2004). Treatment to accelerate the resolution of 
pulmonary edema with aerosolized or intravenous β-adrenergic agonists also failed to 
improve survival (Gao Smith et al 2012). Nutritional supplement with ω-3 fatty acid may be 
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harmful (Rice et al 2011). 
 
Newer approaches, such as targeting the coagulation system, have been considered. 
Recombinant human activated protein C (APC) was found to reduce 28-day mortality in 
patients with severe sepsis (Bernard et al 2001). However, follow-up studies among patients 
with severe sepsis and a low risk of death and in children with severe sepsis were negative 
(Abraham et al 2005, Nadel et al 2007). Furthermore, a recent trial of APC has provided 
evidence that this anticoagulant and anti-inflammatory agent does not have efficacy for 
patients with severe sepsis, the most lethal cause of ALI and ARDS (Ranieri et al 2012). 
Strategies and rationale for anticoagulants for ALI and ARDS will now need to be 
reevaluated. 
 
Explanations for these outcomes are likely multifactorial, the lack of efficacy of many of 
these agents does raise the question of whether or not these treatments may perform better in 
more homogeneous cohorts of patients. Therefore, further research is needed to recommend 
any of these agents. Without therapeutic product currently approved for treatment of 
ALI/ARDS, there is clearly an urgent need for new effective and affordable treatments.  
 
1.3. Ceramide-enriched membrane platforms 
1.3.1. Lipid interactions and domain formation 
The biological membranes of eukaryotic cells are comprised mainly of sphingolipids, 
(glycerol-) phospholipids and cholesterol. Sphingolipids are characterized by a 1, 
3-dihydroxy-2-aminoalkane backbone, also named sphingoid base (Hakomori 1983). 
Sphingosine, the most prevalent backbone of mammalian sphingolipids refers to (2S, 3R, 
4E)-2-amino-4-octadecene-1, 3-diol. Sphingoid bases vary in length of the alkyl chain and 
position and number of the double bonds. Ceramide is generated from sphingosine by 
attachment of a fatty acid via an amide ester bond. The fatty acids in the ceramide moiety also 
vary in chain length and saturation. Thus, ceramide is composed of D-erythro-sphingosine 
and a fatty acid usually containing 2–32 carbon atoms in the acyl chain that are connected 
INTRODUCTION 
- 15 - 
via an amide ester bond. Ceramides are further modified by attachments of headgroups to 
form sphingomyelin, gangliosides, sulfatides, globosides or cerebrosides, for example, 
forming sphingomyelin by reaction with phosphorylcholine (Barenholz et al 1980, Kolesnick 
et al 2000). The most prevalent membrane sphingolipid is sphingomyelin, which consists of a 
very hydrophobic ceramide moiety (a D-erythro-sphingosine bound to a fatty acid by an amide 
ester) and a hydrophilic phosphorylcholine headgroup (Hakomori 1983). The acyl chain of the 
fatty acid may contain 2 to 32 carbon atoms. 
 
In 1972, Singer and Nicolson described the fluid mosaic model of the cell membrane; this 
model suggested a random distribution of lipids and proteins in the cell membrane, which was 
in a liquid-disordered phase. This model predicted free movement of proteins in the lipid 
bilayer, which was based on biophysical experiments that determined the melting 
temperatures of lipids (Singer et al 1972). However, biophysical studies in the last 15 years 
revised this model and suggested the formation of small domains in the cell membrane that 
exist in a liquid-ordered phase and thus form distinct domains in the cell membrane (Brown et 
al 1998, Simons et al 1997). 
 
Sphingomyelin is the most prevalent cellular sphingolipid and synthesized on the luminal side 
of the Golgi apparatus or the plasma membrane. Thus, it localizes predominantly to 
anti-cytoplasmic leaflets of the cell membrane and intracellular vesicles (Emmelot et al 1975, 
Futerman et al 1990, Jeckel et al 1990). This distribution pattern of sphingomyelin, which 
results in lipid bilayer asymmetry, is critical for the genesis of distinct membrane domains 
and, as discussed below, signal transduction. Sphingomyelin consists of a highly hydrophobic 
ceramide moiety and a hydrophilic phosphorylcholine headgroup (Barenholz et al 1980, 
Kolesnick et al 2000). Sphingolipids interact with each other via hydrophilic interactions 
between the sphingolipid headgroups (Brown et al 1998, Kolesnick et al 2000, Simons et al 
1997). In addition, sphingolipids, and in particular the predominant sphingolipid 
sphingomyelin, interact with cholesterol via hydrogen bonds with the hydroxy group in the 
cholesterol molecule and via hydrophobic van der Waal interactions between the ceramide 
moiety and the sterol ring system. These binding forces result in a relatively tight interaction 
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between these lipids and in the spontaneous formation of domains that are in the 
liquid-ordered phase or even of gel-like domains with higher melting temperatures than other 
phospholipids in the cell membrane (Brown et al 1998, Kolesnick et al 2000, Simons et al 
1997). These distinct sphingolipid- and cholesterol-enriched membrane domains were named 
rafts (Simons et al 1997). Recent microscopy studies of cell membranes using the STET 
technique suggest that these rafts have a diameter of less than 20 nm (Eggeling et al 2009). 
Cholesterol and some cholesterol precursors not only interact with sphingolipids but also 
seem to fill the void spaces between bulky sphingolipids and, sterically, to stabilize 
sphingolipid- and cholesterol-enriched domains (Megha et al 2004, Xu et al 2001). Extraction 
of cholesterol from rafts by interference with the cholesterol metabolism employing drugs 
such as filipin, nystatin or methyl-beta-cyclodextrin (Keller et al 1998) destroys rafts 
supporting the critical role of cholesterol for the integrity of at least some rafts. 
 
However, at present only indirect evidence exists to support the presence of rafts in cells 
under in vivo conditions, for instance at physiological temperature. The concept of rafts is still 
somewhat controversial (Munro 2003), since the use of detergents employed in most studies 
characterizing rafts may change the membrane and only cause the formation of rafts (Munro 
2003). Recently, Brugger and co-workers suggested the lipid composition of HIV particles 
released from living cells (Brugger et al 2006). This study demonstrated a high concentration 
of sphingolipids and cholesterol in the viral coat suggesting that viral budding occurs in 
distinct domains of the cell membrane that are enriched with these lipids arguing that rafts 
exist in vivo. 
 
1.3.2. Ceramide synthesis and metabolism 
Diverse stress stimuli, such as cytokines, environmental stress and chemotherapeutic or 
anti-cancer drugs (Hannun et al 2002, Senchenkov et al 2001, Spiegel et al 2002) (Figure 
1.3.2.A.) induce ceramide formation, and therefore ceramide is involved in the regulation of 
cell growth, differentiation, cell cycle arrest and apoptosis. 
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Figure 1.3.2.A. Ceramide formation in response to diverse stress stimuli 
 
Ceramide formation is induced in response to environmental stress, ionic/ultraviolet radiation, heat, 
hypoxia, reperfusion, cytokines and growth factors, tumor necrosis factor, interferon-gamma and 
interleukin-1-beta as well as chemotherapeutic agents/anticancer drugs (Pandey et al 2007). 
 
The hydrolysis of sphingomyelin is catalyzed by the activity of acid, neutral, or alkaline 
sphingomyelinase and results in the generation of ceramide (Gulbins et al 2003, Hannun et al 
2008, Quintern et al 1989). Further, ceramide is generated in membranes by a de novo 
pathway involving the enzyme ceramide synthase (Kolesnick et al 2000) (Figure 1.3.2.B.). 
Recent studies further revealed three additional pathways for the formation of ceramide, i.e. 
by the reverse activity of the acid ceramidase catalyzing synthesis of ceramide from 
sphingosine (Okino et al 2003), by hydrolysis of complex glycosylated lipids (Ishibashi et al 
2007) and by hydrolysis of ceramide-1-phosphate (Mitra et al 2007). Ceramide can also be 
converted into other sphingolipids, such as ceramide-1-phosphate, sphingosine, and 
sphingosine-1-phosphate. 
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Figure 1.3.2.B. Ceramide synthesis and metabolism 
 
Ceramide can be generated from the sphingomyelin via sphingomyelinase pathway (sphingomyelin 
metabolism), degradation of glycosylated sphingolipids or via the de novo synthesis pathway where 
cells synthesize ceramide from serine and palmitoyl-CoA (de novo synthesis). Ceramide can be further 
converted into other sphingolipids such as ceramide-1-phosphate, glycosylated ceramide, sphingosine 
and sphingosine-1-phosphate (Becker et al 2010a).  
 
 
1.3.3. Acid sphingomyelinase (Asm) and ceramide-enriched membrane platforms 
Acid sphingomyelinase (Asm) is the first and best-characterized sphingomyelinase and 
previous study already showed the enzyme critically involved in many forms of cell 
activation reviewed for instance by Gulbins et al. (Gulbins et al 2003). There are two forms of 
Asm, a lysosomal Asm and a secretory Asm that are both derived from the same gene, but 
differ in their glycosylation pattern and are also differentially processed at the NH2-terminus 
(Schissel et al 1998a). Most of Asm seems to reside in classical lysosomes, where it mediates 
the catabolism of sphingomyelin. Asm-deficiency leads to the accumulation of sphingomyelin 
and a lysosomal storage disorder named Niemann-Pick disease type A and B. Many studies 
suggested that the pool of Asm insecretory lysosomes seems to participate in signal 
transduction events (Bao et al 2010, Grassmé et al 2001a, Herz et al 2009, Schissel et al 1996, 
Schissel et al 1998b). Appropriate cellular activation triggers the fusion of secretory 
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lysosomes and the cell membrane, and this fusion results in the exposure of Asm on the outer 
leaflet of the cell membrane (Bao et al 2010, Herz et al 2009).  
 
Usually, Asm hydrolyzes sphingomyelin to ceramide, preferentially at an acidic pH. However, 
because other lipids crucially influence the Michaelis-Menten constant (Km) of the enzyme to 
its substrate, the enzyme seems to be able to hydrolyze sphingomyelin also under almost 
neutral PH conditions (Schissel et al 1996, Schissel et al 1998a). Since Asm is predominantly 
present in the outer leaflet of the cell membrane (Calderon et al 1997, Grassmé et al 2001a, 
Grassmé et al 2001b), the hydrolysis of sphingomyelin results in ceramide-enriched 
membrane domains that are primarily in the outer leaflet of the cell membrane, or in general 
in anti-cytoplasmic leaflets of cellular membranes. 
 
Changes in the glycosylation pattern of Asm result in the expression of a secretory form of 
Asm that is released upon stimulation, for instance via interleukin-1 receptors (Schissel et al 
1996, Schissel et al 1998b). Further, several studies demonstrated that stimuli such as CD95, 
DR5 and CD40 or infection with some pathogenic bacteria and viruses mobilize intracellular 
vesicles/secretory lysosomes, a process that results in exposure of Asm on the outer leaflet of 
the cell membrane (Cremesti et al 2001, Dumitru et al 2006, Grassmé et al 2001a, Grassmé et 
al 2002b, Grassmé et al 2003a, Grassmé et al 2003b, Grassmé et al 2005). 
 
Lysosomal Asm and secretory Asm hydrolyze sphingomyelin from the plasma membrane and 
generate ceramide within cell membranes. The release of ceramide within the cell membrane 
alters the biophysical characteristics of membranes, because they spontaneously self-associate 
to small, highly hydrophobic, and ordered ceramide-enriched membrane microdomains 
(Holopainen et al 1998, Kolesnick et al 2000, Nurminen et al 2002). These microdomains 
spontaneously fuse to larger ceramide-enriched membrane domains, also named membrane 
platforms, that can reach a width of up to 5 µm (Gulbins et al 2003). Ceramide-enriched 
membrane platforms seem to be very hydrophobic and stable, since ceramide molecules are 
highly packed and ordered. Furthermore, the presence of ceramide excludes cholesterol 
molecules from membrane domains, at least in artificial membranes, suggesting that ceramide 
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also changes the composition of rafts (Megha et al 2004, Megha et al 2006) with an increased 
concentration of ceramide and a decreased concentration of cholesterol, respectively. 
 
1.3.4. Visualization of ceramide-enriched membrane domains 
The formation of ceramide-enriched membrane platforms in the plasma membrane upon 
generation of ceramide might be critical for the signaling function of ceramide, which were 
demonstrated by several methods in vivo and in vitro.  
 
First, activation of several receptors, such as CD95, DR5, CD40, and the platelet-activating 
factor receptor, but also some bacterial and viral infections or stress stimuli, trigger the 
surface exposure of Asm and the formation of ceramide-enriched membrane platforms by 
fluorescence and electron microscopy (Cremesti et al 2001, Dumitru et al 2006, Grassmé et al 
2001a, Grassmé et al 2002b, Grassmé et al 2003a, Grassmé et al 2003b, Grassmé et al 2005) 
(Figure 1.3.4.). Secondly, studies on phosphatidylcholine/sphingomyelin-composed 
unilamellar vesicle that were treated with sphingomyelinase immobilized onto a microbead 
confirmed the formation of ceramide-enriched membrane macrodomains (Holopainen et al 
1998, Nurminen et al 2002). Furthermore, in vitro studies also indicated the formation of 
distinct membrane domains by magnetic resonance spectroscopy and atomic force 
microscopy studies, which revealed laminar phase separation of long chain ceramides in 
glycerol-phospholipid/cholesterol bilayers and formation of stable, distinct domains that 
correspond with a transition of fluid phospholipid bilayers into a gel-like phase  (Huang et al 
1999, ten Grotenhuis et al 1996, Veiga et al 1999). Finally, Ira and Johnston used a 
combination of atomic force microscopy and total internal reflection fluorescence to directly 
visualize clustering of small membrane domains into larger domains in artificial membranes 
composed of 1, 2-dioleoyl-sn-glycero-3-phosphocholine/sphingomyelin/cholesterol mixtures 
upon treatment with Bacillus cereus sphingomyelinase to generate ceramide or incubation 
with C16-ceramide. The studies revealed that enzymatic hydrolysis of sphingomyelin to 
ceramide in model membranes resulted in very rapid reorganization of the membrane, 
clustering of domains and the formation of larger distinct domains that presumably 
correspond to ceramide-enriched membrane domains. The addition of C16-ceramide also 
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resulted in the formation of larger domains in these bilayers, albeit with different kinetics and 
less impact on membrane organization (Ira et al 2008).  
 
 
 
Figure 1.3.4. Ceramide forms ceramide-enriched membrane platforms in the cell membrane 
 
Jurkat T cells (0.5 x·106 cells/sample) were centrifuged for 5 min at 1400 rpm, resuspended in 90 µl 
PBS. Cells were rested for 8 min at 37 ℃, shaked at 400 rpm, and treated with 1 µM C16 ceramide for 
5 min. Cells were fixed in 1% PFA for 20 min, washed once, unspecific binding sites were blocked 
with 2% fetal calf serum (FCS) and stained with anti-ceramide antibody clone 15B4 (1:20 dilution). 
Cells were incubated on ice for 45 min, washed once and incubated for 45 min on ice with 100 µl of a 
Cy3 F (ab) 2 fragment of a donkey anti-mouse IgM (1:300). Cells were washed once and analyzed on 
a fluorescence microscope (Grassmé et al 2007).  
 
1.3.5. Function of ceramide-enriched membrane platforms 
Ceramide-enriched membrane domains may have several biological functions. First, the 
composition and fluidity of ceramide-enriched membrane domains differ from the 
surrounding areas in biological membranes, which are perfect structures to sort proteins in 
cells and to provide a mean for the spatial re-organization of receptors and/or intracellular 
signaling molecules within these membrane domains. Trapping and clustering of activated 
receptors in ceramide-enriched membrane domains was demonstrated for CD95, DR5, or 
CD40 (Dumitru et al 2006, Grassmé et al 2001a, Grassmé et al 2002a, Grassmé et al 2002b), 
but many more receptors may use the mechanism of clustering to reach a very high density in 
circumscribed areas of the cell membrane. The reorganization of receptors within 
ceramide-enriched membrane domains results in a very high receptor density within a 
relatively small area of the cell membrane, which is required for the transmission of signals 
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via many receptor molecules. Receptor aggregation and trapping in ceramide-enriched 
membrane domains may limit lateral diffusion and, thus, stabilize the interaction of a ligand 
with its receptor, in particular if the ligand is also trapped in distinct membrane domains. The 
interaction of ligand-bound receptors with the very hydrophobic ceramide-enriched 
membrane platform and/or individual ceramide molecules may in addition stabilize 
conformational changes that may occur upon activation of a receptor by its ligand. 
Furthermore, ceramide-enriched membrane domains may sort intracellular signalling 
molecules, for instance via farnesyl or geranyl-moieties, which may result in the spatial 
association of activated receptors with signalling molecules that transmit the signal from the 
receptor into the cell, while at the same time inhibitory molecules are excluded from this area 
of the cells. Thus, in general, ceramide-enriched membrane platforms may primarily function 
to re-organize receptor and signaling molecules in and at the cell membrane to facilitate and 
amplify signaling processes via a specific receptor.  
 
Second, in addition to its function in membrane platforms, ceramide was also shown to 
directly interact and regulate several molecules including cathepsin D (Heinrich et al 1999), 
phospholipase A2 (Huwiler et al 2001), kinase suppressor of Ras (identical to 
ceramide-activated protein kinase) (Zhang et al 1997), ceramide-activated protein 
serine-threonine phosphatases(CAPP) (Dobrowsky et al 1993), protein kinase C isoforms 
(Muller et al 1995) and c-Raf-1 (Yao et al 1995). A direct binding of ceramide was 
demonstrated for cathepsin D (Heinrich et al 1999), phospholipase A2 (Huwiler et al 2001) 
and CAPP (Chalfant et al 2004, Dobrowsky et al 1993), although at present the details and the 
specificity of ceramide-protein interactions are still unknown except for cathepsin D. 
Cathepsin D binds ceramide within a short domain of the cathepsin D molecule, which 
triggers the autocatalytic cleavage of cathepsin D to its active form and promotes, via still 
unknown mechanisms, the translocation of active cathepsin D from lysosomes into the 
cytoplasm where cathepsin D triggers cell death via Bid, Bax and Bak (Heinrich et al 1999, 
Schneider-Brachert et al 2004). Ceramide might facilitate the transport of cathepsin D over 
the double membrane by forming a hydrophobic coat around the protein, the formation of 
ceramide channels (Siskind et al 2000) or by a very short disruption of the membrane bilayer. 
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Third, ceramide has been shown to regulate several ion channels. Ceramide inhibits the 
potassium channel Kv1.3 and the calcium release activated calcium channel in lymphocytes 
(Bock et al 2003, Gulbins et al 1997, Lepple-Wienhues et al 1999, Szabo et al 1996). This is 
also consistent with the finding that Kv1.3 localizes to ceramide-enriched membrane domains 
after stimulation via CD95 (Bock et al 2003, Lepple-Wienhues et al 1999). However, these 
studies do not exclude that ceramide also affects ion channels by a direct interference or by 
the change of the lipid composition in ceramide-enriched membrane platforms. The calcium 
release activated calcium channels that are central in the regulation of cellular Ca2+ 
concentrations and, thus, involved in multiple cellular pathways (Lee et al 2004), are also 
inactivated upon stimulation of cells via CD95 (Hannun et al 2000) or the TNF-receptor 
(Zemann et al 2007) or upon treatment with synthetic ceramides, C2, C6 and C16-ceramides, 
respectively. Genetic deficiency of the Asm abrogated the inhibition of the calcium release 
activated calcium channels by CD95 and TNF-receptor stimulation. Finally, 
ceramide-molecules seem to form channels or pores, at least in the outer mitochondrial 
membrane (Siskind et al 2000, Siskind et al 2006). These channels might be important for the 
induction of apoptosis, although it is unknown whether ceramide pores are also formed in 
vivo. The regulation of ion channels by ceramide is a poorly investigated field, although its 
potential for many physiological and pathophysiological processes appears immense. 
 
In summary, ceramide-enriched membrane domains serve the temporal and spatial 
organization of signaling molecules to regulate multiple cell functions. However, the 
mechanisms responsible for the action of ceramide on these downstream targets are not fully 
understood.  
 
1.3.6. Asm/ceramide in bacterial infections 
Asm/ceramide in internalization of bacteria. Numerous studies, using either genetic 
deficiency of pharmacological inhibition of Asm, demonstrated that the activation of Asm and 
the concomitant release of ceramide upon the infection of human epithelial and myeloid cells 
with Neisseria gonorrhoeae (Grassmé et al 1997, Hauck et al 2000), the infection of 
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endothelial cells with S. aureus (Esen et al 2001), the infection of pulmonary epithelial cells 
and fibroblasts with Pseudomonas aeruginosa (P. aeruginosa) (Grassmé et al 2003b), the 
infection of immature dendritic cells with Escherichia coli (Falcone et al 2004), the infection 
of macrophages with Listeria monocytogenes (Utermohlen et al 2003) or Salmonella 
typhimurium (McCollister et al 2007), and the infection of mononuclear cells with 
Mycobateria avium (Utermohlen et al 2008), resulted in uptake of the bacteria (Figure 
1.3.6.A.). The bacteria very rapidly activate the enzyme, induce a rapid surface translocation 
of the Asm and trigger the release of ceramide and, thus, the formation of ceramide-enriched 
membrane platforms, which seem to be central for the uptake of pathogens. 
 
Asm/ceramide in bacterial killing. Infection of macrophages with Listeria monocytogenes 
(Utermohlen et al 2008) or Salmonella typhimurium (McCollister et al 2007) results in 
intracellular killing of the bacteria. In wild-type macrophages, the phagosome rapidly fuses 
with the lysosome to form a phago-lysosome and to kill and digest the bacteria. In contrast, 
Asm-deficient macrophages were unable to kill the bacteria. Studies with Listeria 
monocytogenes also demonstrated that Asm deficient macrophages impaired the maturation 
and fusion of intracellular phagosomes with lysosomes and led to development of sepsis and 
greatly increased mortality of Asm deficient mice (Schramm et al 2008, Utermohlen et al 
2003). Moreover, Yang and colleagues showed that the Asm is also required to produce ROS 
upon infection, which also kills the pathogens. Deficiency of the Asm prevents ROS release 
and reduces bacterial killing (Zhang et al 2008) (Figure 1.3.6.B.).  
 
Asm/ceramide in cell death induced by bacterial infection. In addition to mediating the 
internalization of pathogens and fusion of intracellular vesicles, Asm and ceramide have been 
shown to be also crucial for the induction of cell death on infection of endothelial cells with S. 
aureus (Esen et al 2001), on infection of immature dendritic cells with E. coli (Falcone et al 
2004), on infection of pulmonary epithelial cells and fibroblasts with P. aeruginosa (Grassmé 
et al 2003b, Kannan et al 2008). The molecular mechanisms by which Asm and ceramide are 
involved in induction of cell death are still not well-known. Below is a summary of possible 
mechanisms: a. Ceramide-enriched membrane platforms cluster CD95 and induce cell death 
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on infection of epithelial cells with P. aeruginosa (Becker et al 2012, Grassmé et al 2000). b. 
Ceramide-enriched membrane platforms are required to internalize P. aeruginosa, induce 
apoptosis and regulate the cytokine response in infected cells. Impaired bacterial killing in 
Asm-deficient mice induced overwhelming inflammation and cell death (Grassmé et al 2003b, 
Kannan et al 2006) (Figure 1.3.6.C.). 
 
Asm/ceramide in cytokine release induced by bacterial infection. The release of cytokines, 
which is moderately increased in the lungs of wild-type mice upon infection, is uncontrolled 
and exaggerated in Asm-deficient mice infected with P. aeruginosa, resulting in a cytokine 
storm and the death of the mice (Grassmé et al 2003b). This finding is confirmed by Kannan 
and co-workers’ work (Kannan et al 2006). However, the mechanisms that mediate the 
activation of Asm and cytokines release by P. aeruginosa require definition. 
 
Asm/ceramide in host survival. Our group revealed that Asm/ceramide are critical for the 
internalization of P. aeruginosa into epithelial cells and fibroblasts, the induction of death of 
infected cells, and controlled release of cytokines critical, finally facilitating the mice survival 
P. aeruginosa infection (Grassmé et al 2003b). Schramm and colleagues ascertained the role 
of Asm/ceramide in Listeria monocytogenes infection by demonstrating that Asm-deficient 
macrophages showed impaired phagolysosome fusion and maturation correlated with severe 
sepsis and increased mortality of Asm-deficient mice (Schramm et al 2008). Moreover, recent 
studies showed that Asm-deficienct mice controled the bacteria in small granulomas to protect 
the mice from uncontrolled inflammation upon Mycobacteria avium infection, but not 
wild-type mice (Utermohlen et al 2008). 
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Figure 1.3.6. Functions of Asm and ceramide during bacterial infections 
 
Asm functions in the outer leaflet of the cell membrane to mediate internalization of pathogens (A) 
and in lysosomes to mediate fusion of phagosomes with lysosomes (B). Asm also seems to be 
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involved in maturation of phagolysosomes (B). Finally, surface and intracellular ceramide generated 
by Asm activity is important for induction of cell death upon infection with some pathogens (C) 
(Grassmé et al 2008). 
 
1.4. Redox signaling 
1.4.1. Overview of Reactive oxygen species (ROS) 
ROS are chemically reactive molecules containing oxygen. Examples include oxygen ions 
and peroxides. ROS are formed as a natural byproduct of the normal metabolism of oxygen 
and have important roles in cell signaling and homeostasis (Devasagayam et al 2004). Various 
ROS (Figure 1.4.1.), including O2.-, H2O2, .OH, and ONOO.-, participate in cell signaling 
under certain physiological or pathological conditions. The most important of these ROS is 
O2.-, which is unstable and short-lived because it has an unpaired electron, and it is highly 
reactive with a variety of cellular molecules, including proteins and DNA. O2.- is reduced to 
H2O2 by superoxide dismutase (SOD), an enzyme which catalyzes the dismutation of 
superoxide radicals (O2.- + O2.- + 2H+ -- O2 + H2O2) (McCord et al 1969). Both O2.- and H2O2 
can diffuse from their sites of generation to other cellular locations. H2O2 is further reduced to 
generate the highly reactive .OH through the Haber-Weiss or Fenton reaction under 
pathological conditions. In contrast to O2.- and H2O2, .OH is highly reactive and, therefore, 
causes primarily local damage. In addition, O2.- can also interact with NO to form another 
reactive oxygen free radical, ONOO.-. Under physiological conditions, O2.- preferably 
produces H2O2 via the dismutation reaction. However, when excess O2.- is produced, a 
substantial amount of O2.- reacts with NO to produce ONOO.- (Figure 1.4.1.).  
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Figure 1.4.1. Possible oxidant generating reactions with stimulated neutrophils. NOS, nitric 
oxide synthase; MPO, myeloperoxidase (Hampton et al 1998) 
 
1.4.2. ROS production and regulation 
O2.- is the progenitor of other ROS. In mammalian cells, many pathways are involved in the 
production of O2.-, including nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, 
xanthine oxidase, mitochondrial respiration chain, and NO synthase-uncoupling. NADPH 
oxidase has been detected in nearly every tissue, and in many cells, such as those in 
phagocytes and vascular cells, it is the primary source of ROS. Recent studies suggest that 
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NADPH oxidase localizes to specific subcellular compartments, including lamellipodial focal 
complexes and focal adhesions, membrane ruffles, caveolae and lipid rafts, endosomes, 
sarcoplasmic reticulum, and the nucleus. NO synthases normally localize in caveolae and 
function as homodimers to synthesize NO. When exposed to oxidative or nitrosative stress, 
NOS becomes structurally unstable (“uncoupling state”) and exhibits NADPH oxidase 
activity resulting in O2.- formation. Given that ROS are short-lived and diffusible, the 
localization of ROS signals in specific subcellular compartments suggests that mammalian 
cells contain temporally and spatially organized redox signaling pathways that regulate 
various cellular functions. 
 
An antioxidant is a molecule that inhibits the oxidation of other molecules. Oxidation is 
a chemical reaction that transfers electrons or hydrogen from a substance to an oxidizing 
agent. Oxidation reactions can produce free radicals. In turn, these radicals can start chain 
reactions. When the chain reaction occurs in a cell, it can cause damage or death to the cell. 
Antioxidants terminate these chain reactions by removing free radical intermediates, and 
inhibit other oxidation reactions. They do this by being oxidized themselves, so antioxidants 
are often reducing agents such as thiols, ascorbic acid, or polyphenols (Sies 1997).  
 
ROS formation and redox signaling are well known to play a major role in physiology as well 
as in a variety of pathologies. For instance, in the heart, cardiomyocyte differentiation, and 
excitation-contraction coupling are under tight redox control (Burgoyne et al 2012, Steinberg 
2013). On the other hand, cardiac pathologies, such as ischemia/reperfusion injury, heart 
failure, and arrhythmias can be prevented or blocked by inhibiting specific processes that 
result in ROS generation in several experimental models (Anderson et al 2014, Kaludercic et 
al 2014, Takimoto et al 2007, Youn et al 2013). Thus, it appears that pro-oxidant generation 
and antioxidant defense need to be tightly regulated (Chance et al 1979). Indeed, disruption of 
redox signaling and control, and imbalance in favor of pro-oxidant species is defined 
oxidative stress, term first coined in 1985 (Jones 2006, Sies et al 1985). Conversely from 
pathological modifications (Chance et al 1979, Powers et al 2008), it appears that 
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physiological redox signaling is characterized by reversible oxido-reductive modifications, 
confined both spatially and temporally in subcellular compartments and microdomains. 
 
1.5. Endothelial Barrier 
1.5.1. Overview of Endothelial Barrier 
The vascular endothelium lining the inner surface of blood vessels serves as the first interface 
for circulating blood components to interact with cells of the vascular wall and surrounding 
extravascular tissues. In addition to regulating blood delivery and perfusion, a major function 
of vascular endothelia, especially those in exchange microvessels (capillaries and 
postcapillary venules), is to provide a semipermeable barrier that controls blood-tissue 
exchange of fluids, nutrients, and metabolic wastes while preventing pathogens or harmful 
materials in the circulation from entering into tissues. 
 
Blood fluid, solutes, and even circulating cells can cross the endothelium via two routes: 
through the cell body (transcellular), or between the cells (paracellular, or intercellular)(Mehta 
et al 2006) (Figure 1.5.1.). The transcellular pathway, which contributes very little to the 
leakage of events in pathophysiological conditions, includes vesicle-mediated endocytosis, 
vacuole-vesicular organelles (VVOs) and regulated water channels (aquaporins). On the other 
hand, the paracellular pathway, which is responsible for the majority of leakage of blood fluid 
and proteins across the microvascular endothelium under pathophysiological conditions, is 
mainly mediated by junctional proteins (Figure 1.5.1.). 
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Figure 1.5.1. Transcellular and paracellular permeability pathways across the microvascular 
endothelium  
 
Barrier function of the microvasculature is provided by closely apposed endothelial cells of 
themicrovessel walls. The thin layer of endothelium is attached to the microvascular basement 
membrane via endothelial membrane-bound integrins. Endothelial cells are joined together by 
intercellular junction proteins that allow the selective passage of solutes and fluids across the 
endothelium. Intercellular junctions can become more porous, or even form large-sized gaps under 
pathophysiological conditions. The glycocalyx forms a selective filter across the endothelial luminal 
surface, forming an additional permeability barrier. Solutes can also traverse the cell interior via 
receptor-mediated vesicle endocytosis originating at caveolae, or via vacuole-vesicular organelles 
(VVOs) that can fuse with trafficking vesicles and form open transcellular pores. Transcellular water 
transport can occur in parallel with other fluxes, through regulated water channels (aquaporins) in the 
endothelial cell membrane (Yuan et al 2010). 
 
 
Two types of intercellular junctions have been characterized as the cell–cell adhesive barrier 
structures in the microvascular endothelium: the adherens junction (AJ) and tight junction 
(TJ) (Komarova et al 2010, Mehta et al 2006). The former has been identified in nearly all 
types of vascular beds, especially in the peripheral microvasculature. Vascular endothelial 
(VE)–cadherin is believed to be the most important protein in forming the molecular basis, as 
well as regulating the function of AJs. Intracellularly, VE–cadherin is connected to the actin 
cytoskeleton via a family of catenins (α-, β-, γ-, and p120-catenins) (Mehta et al 2006). Thus, 
the stability of the VE–cadherin–catenin–cytoskeleton complex is essential to the 
maintenance of endothelial barrier function (Alcaide et al 2008, Sallee et al 2006, Vincent et 
al 2004). 
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Endothelial tight junctions are composed of interactions of tight junction proteins: occludin, 
claudins, and JAM-A (Abbott et al 2010, Hawkins et al 2005, Mehta et al 2006), which are 
connected to the actin cytoskeleton via zona occludens proteins (ZO-1, ZO-2) and α-catenin. 
ZO proteins play both structural and signaling roles in tight junctions (Hawkins et al 2005, 
Shen et al 2009). 
 
During host defense against infection or tissue injury, endothelial barrier dysfunction occurs 
as a consequence as well as cause of inflammatory responses. Endothelial barrier dysfunction 
is characterized by leakage of fluid, proteins, or small molecules, measured as excessive flux 
of these molecules across the endothelium (termed hyper-permeability), and clinically 
manifests as accumulation of plasma-like, protein-rich fluid in the extravascular space leading 
to tissue swelling (termed edema) (Yuan et al 2010).  
 
1.1.1. Leukocytes and Endothelial Barriers  
Endothelial hyper-permeability occurs following trauma, pathogen infection, or chronic 
disease states, which is a generalized response to inflammation (Kumar et al 2009, Lush et al 
2000). A hallmark of inflammation is extravasation of leukocytes from the blood to the tissue 
across the microvascular endothelium (Cavanagh et al 1998, Lewis et al 1986, Nathan 2006). 
Leukocytes, which are white blood cells circulating in the blood, include lymphocytes 
(T-cells, B-cells, and natural killer cells), monocytes, and polymorphonuclear (PMN) 
granulocytes (neutrophils, eosinophils, and basophils) (Moser et al 2010). 
 
Neutrophil extravasation is a multi-stage process: rolling, activation, adhesion, and 
transmigration, requiring complex interactions of PMNs or other leukocytes with the 
microvascular endothelium (Figure 1.5.2.) (Butcher 1991, Kubes 2002). Leukocyte 
trans-endothelial migration occurs in response to endothelial hyper-permeability caused by 
bacterial invasion or tissue inflammatory injury. In the presence of a compromised 
microvascular endothelial barrier, leukocytes can become immobilized by firm adhesion to 
the micro-vessel luminal surface and cross the endothelium into the tissues step by step. 
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Generally, PMNs are the first leukocyte cell type to arrive at the site of barrier dysfunction 
(Nathan 2006). After and/or during transmigration across the micro-vessel wall, PMNs will 
become activated and undergo a respiratory burst, characterized by release of granule 
secretions of numerous compounds (Lewis et al 1986), which can attack and liquify tissue 
surrounding the compromised vasculature (pus formation) (Nathan 2006). PMNs also secrete 
chemokines or induce endothelial expression of chemokines (Middleton et al 1997) to attract 
other leukocytes (macrophages, monocytes, and immune cells) to the site of inflammation. 
Hence, leukocyte activation and migration across the endothelium are both cause and 
consequence of endothelial hyper-permeability and barrier dysfunction (Nathan 2006). 
 
 
 
Figure 1.5.2. The stages of neutrophil extravasation 
 
Neutrophil transmigration is a sequential process of (1) rolling along the microvessel wall, (2) firm 
adhesion to the endothelium (via interactions with cell surface adhesion molecules), (3) diapedesis 
(transmigration) coordinated by interactions between cell surface glycoproteins, followed by migration 
into the extravascular space, and (4) neutrophil activation, characterized by granule secretions of 
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hyper-permeability-inducing agents (oxygen free radicals (O2.-), NO, cytokines, and arachidonic acid 
metabolites: leukotriences and prostaglandins), further contributing to barrier dysfunction (Yuan et al 
2010). 
 
1.6. Aims of the study 
Sepsis is a devastating and complex syndrome and continues to be a major cause of morbidity 
and mortality among critically ill patients at the surgical intensive care unit setting in the 
United States (Angus et al 2001, Dombrovskiy et al 2007, Kung et al 2008, Martin et al 2003, 
Melamed et al 2009, Russell 2006). Antibiotics alone are often insufficient to cure patients 
with S. aureus–induced sepsis. Although treatment with effective doses of bactericidal 
antibiotics indeed prevents the bacterial burden, antibiotics often fail to prevent fatal lung 
edema after septic infection with S. 
aureus. 
 
Our group has demonstrated that Asm/ceramide system activates several receptors, mediates 
entry of several microorganisms into cells and participates in signal transduction events. 
Particularly, we discovered S. aureus infection activates the Asm/ceramide system, and 
finally induces apoptosis of human endothelial cells (Esen et al 2001). However, it is 
unknown whether the Asm/ceramide system also plays an important role in endothelial cells 
injury and lethal lung edema induced by systemic S. aureus infection. The endothelium is a 
highly dynamic cell layer that is involved in a multitude of physiological functions, thus, it is 
very important to emphasize the potential value of the endothelium as a target for lethal lung 
edema therapy in sepsis. 
 
The present thesis first defines the role of Asm in regulating lung edema induced by systemic 
S. aureus infections. Because ceramide is an important signaling molecule that regulates redox 
signaling (Zhang et al 2007), the present study further investigated whether lung edema induced 
by S. aureus infections is prevented by Asm deficiency. The importance of Asm for lung injury 
was tested in Asm-deficient mice. 
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Furthermore, the mechanism of Asm activation inducing lung edema was addressed. It was 
investigated whether S. aureus infections induces activation of Asm, subsequent ceramide 
release and activation of ROS, leading to degradation of tight junctions, neutrophils trafficking 
and lung edema. 
 
The last part of the study focused on the clinical significance of the Asm/ceramic system in a S. 
aureus sepsis. It was tested whether treatment of already septic mice with Asm inhibitor 
amitriptyline prevents the development of lung edema and whether the combination of 
amitriptyline and antibiotic prevents sepsis. 
 
Our results will increase the understanding of the signaling mechanism that Asm deficiency 
protects lung edema induced by S. aureus infections. Moreover, the study will announce a 
novel approach to treat severe systemic and often lethal infections and to prevent lung injury in 
patients with incipient sepsis. 
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2. MATERIALS 
2.1. Chemicals 
Aqua ad Injectabilia DeltaSelect GmbH, Dreieich 
Acetic acid (C2H4O2) Merck, Darmstadt 
Acetone Sigma-Aldrich Chemie GmbH, Steinheim 
Adenosine Tri-Phosphate (ATP) Sigma-Aldrich Chemie GmbH, Steinheim 
Amitriptyline Sigma-Aldrich Chemie GmbH, Steinheim 
β-mercaptoethanol Sigma-Aldrich Chemie GmbH, Steinheim 
Bromphenol blue Sigma-Aldrich Chemie GmbH, Steinheim 
C16-Ceramide  Biomol, PA, USA 
Calcium chloride (CaCl2) Sigma-Aldrich Chemie GmbH, Steinheim 
Cardiolipin Sigma-Aldrich Chemie GmbH, Steinheim 
Chloroform (CHCl3) Ridel-de Haen, Seelze 
CDP-STAR with Nitro-Block II enhancer PerkinElmer, Boston, USA 
DABCO (1,4-Diazabicyclo(2,2,2)octane) Sigma-Aldrich Chemie GmbH, Steinheim 
Deoxycholic acid (C24H40O4) Sigma-Aldrich Chemie GmbH, Steinheim 
Dithiothreitol (DTT) Carl-Roth GmbH & Co, Karlsruhe 
Dimethylsulfoxid (DMSO) Sigma-Aldrich Chemie GmbH, Steinheim 
Eosin (gelblich) E.Merk, Darmstadt 
Ethidium bromide Sigma-Aldrich Chemie GmbH, Steinheim 
Ethanol (C2H5OH) Sigma-Aldrich Chemie GmbH, Steinheim 
Ethylenediamine Tetraacetic Acid 
(EDTA) 
Serva Electrophoresis GmbH, Heidelberg 
Evan’s Blue Dye Sigma-Aldrich Chemie GmbH, Steinheim 
Eukitt® quick-hardening mounting 
medium 
Formamide                             
Sigma-Aldrich Chemie GmbH, Riedstrasse  
Sigma-Aldrich Chemie GmbH, Steinheim    
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Glucose Sigma-Aldrich Chemie GmbH, Steinheim 
Glycerol  Fluka Chemie GmbH, Buchs 
H2DCFDA Molecular Probes, Eugene, OR 
HEPES Carl-Roth GmbH & Co, Karlsruhe 
Hydrochloric acid (HCl) Sigma-Aldrich Chemie GmbH, Steinheim 
Hematoxylin Carl-Roth GmbH & Co, Karlsruhe 
Imidazole (C3H4N2)  Sigma-Aldrich Chemie GmbH, Steinheim 
Isopropanol Sigma-Aldrich Chemie GmbH, Steinheim 
Ketamine Ceva Tiergesundheit GmbH, Duesseldorf 
Magnesium chloride (MgCl2) Sigma-Aldrich Chemie GmbH, Steinheim 
Magnesium sulphate (MgSO4) Sigma-Aldrich Chemie GmbH, Steinheim 
Methanol (CH3OH) Fluka Chemie GmbH, Buchs 
Methicillin Sigma-Aldrich Chemie GmbH, Steinheim 
Mowiol Kuraray Specialities Europe GmbH, 
Frankfurt 
N-acetylcysteine Sigma-Aldrich Chemie GmbH, Steinheim 
N-octylglucopyranoside Sigma-Aldrich Chemie GmbH, Steinheim 
Paraformaldehyde (PFA) Sigma-Aldrich Chemie GmbH, Steinheim 
Paraplast plus Tissue Embedding Medium Leica Microsystems GmbH, Netherlands 
Pepsin Invitrogen, Frederick, USA 
Phosphatase inhibitor Sigma-Aldrich Chemie GmbH, Steinheim 
Potassium chloride (KCl) Sigma-Aldrich Chemie GmbH, Steinheim 
Potassium dihydrogenphosphate 
(KH2PO4) 
Sigma-Aldrich Chemie GmbH, Steinheim 
Protease inhibitor Carl-Roth GmbH & Co, Karlsruhe 
RPMI-1640 Gibco/Invitrogen, Karlsruhe, Germany 
Saponin Serva Electrophoresis GmbH, Heidelberg 
Sodium acetate (CH3COONa)   Sigma-Aldrich Chemie GmbH, Steinheim 
Sodium chloride (NaCl) Carl-Roth GmbH & Co, Karlsruhe 
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Sodium dodecyl sulphate (SDS)   Serva Electrophoresis GmbH, Heidelberg 
Sodium fluoride (NaF)   Sigma-Aldrich Chemie GmbH, Steinheim 
Sodium hydroxide (NaOH) Sigma-Aldrich Chemie GmbH, Steinheim 
Sodium phosphate (Na2HPO4)    Merck, Darmstadt 
Sodium pyrophosphate (Na4P2O7) Sigma-Aldrich Chemie GmbH, Steinheim 
Surgipath Paraplast Leica Microsystems GmbH, Netherlands 
Taq Polymerase   Invitrogen, Karlsruhe, Germany 
Tiron Fluka Chemie GmbH, Buchs 
Tryptic soy broth (TSB)   BD Biosciences, Heidelberg, Germany 
Tris-HCl and Tris-Base Carl-Roth GmbH & Co, Karlsruhe 
Triton X-100   Sigma-Aldrich Chemie GmbH, Steinheim 
Tween-20 Sigma-Aldrich Chemie GmbH, Steinheim 
Vancomycin Sigma-Aldrich Chemie GmbH, Steinheim 
Xylazin   Ceva Tiergesundheit GmbH, Duesseldorf 
Xylene Applichem GmbH, Darmstadt, Germany 
 
2.2. Tissue culture materials 
Cell dissociation buffer enzyme-free Gibco/Invitrogen, Karlsruhe 
DMEM (EAGLE) Gibco/Invitrogen, Karlsruhe 
Fetal Calf Serum (FCS) Gibco/Invitrogen, Karlsruhe 
L-Glutamine Gibco/Invitrogen, Karlsruhe 
MEM non-essential aminoacids Gibco/Invitrogen, Karlsruhe 
Penicilin/Streptomycin Gibco/Invitrogen, Karlsruhe 
Sodium pyruvate Gibco/Invitrogen, Karlsruhe 
Tissue culture flasks 75 cm² TPP, Trasadingen, Switzerland 
Tissue culture flasks 25 cm² TPP, Trasadingen, Switzerland 
Tissue culture test plates TPP, Trasadingen, Switzerland 
Trypsin Gibco/Invitrogen, Karlsruhe 
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2.3. Antibodies  
Alkaline phosphatase-coupled secondary Santa Cruz Biotechnology, CA, USA 
antibodies  
Anti-E-cadherin(H-108) rabbit IgG Santa Cruz Biotechnology, CA, USA 
Anti- Ly-6G and Ly-6C (GR1) rat IgG BD Biosciences, Heidelberg, Germany 
Anti-Occludin rabbit IgG Invitrogen, CA, USA 
Anti-ZO1 rabbit IgG Invitrogen, CA, USA 
Anti-ZO2 (H-110) rabbit IgG Santa Cruz Biotechnology, CA, USA 
Cy3-donkey-anti-rabbit IgG   Jackson Immunoresearch, West Grove, PA, 
USA 
Cy3-donkey anti-rat IgG Jackson Immunoresearch, West Grove, PA, 
USA 
FITC-labled Isolectin B4 Vector Laboratories, CA, USA 
 
2.4. PCR primers 
Asm-PA 1-2 
5´-CGA GAC TGT TGC CAG ACA TC-3´ 
Hermann GbR, Freiburg 
Asm-PA 2-2 
5´-GGC TAC CCG TGA TAT TGC TG-3´ 
Hermann GbR, Freiburg 
Asm-PS-2 
5´-AGC CGT GTC CTC TTC CTT AC-3´ 
Hermann GbR, Freiburg 
Myco P1 
5´-GTG CCA GCA GCC GCG GTA ATA 
C-3´ 
Hölle & Hüttner AG, Germany 
Myco P4 
5´-TAC CTT GTT ACG ACT TCA CCC 
CA-3´ 
Hölle & Hüttner AG, Germany 
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2.5. Cell lines  
EOMA CRL-2586 established murine endothelial cell line 
 
The cell line was tested monthly by PCR to exclude mycoplasma contamination. 
 
2.6. Animals 
Asm-deficient mice were kindly provided by Dr. R. Kolesnick (Memorial Sloan-Kettering 
Cancer Center, NY, USA) and backcrossed for more than 10 generations on a C57BL/6 
background. Syngenic wild-type littermates from the same heterozygous breeding were used 
as control.  
 
The mice used in the present study show the earliest clinical manifestation of Niemann-Pick 
disease type A at approximately 12 weeks of age; therefore, all the Asm-deficient mice used 
in our experiments were younger than 10 weeks of age, before any biochemical, histological 
or clinical manifestations of Niemann-Pick disease type A were apparent. This excluded that 
the effects observed in the Asm-deficient cells were due to altered cellular processes but 
instead, were dependent on the lack of Asm. Wild-type and Asm-deficient mice were 
propagated in the Animal Facility of the Uniklinikum Essen. The genotype was verified by 
PCR analysis.  
 
Mice were housed in pathogen-free conditions under diurnal lighting alternated with a dark 
phase between 18:00–6:00, allowed daily food “Zuchthaltungsfutter Maus-Ratte 10 H 10” 
(Eggersmann) and water ad libitum. All mice were repeatedly tested for the presence of 
pathogens and were free of any pathogens according to the criteria of the Federation of 
Laboratory Animal Science Associations. 
 
2.7. Radioactive substances 
[32P] gamma-ATP Hartmann Analytic, Braunschweig 
[14C] Sphingomyelin Perkin Elmer, Boston, MA, USA 
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2.8. Other materials 
Coverslips 12 mm diameter Carl-Roth GmbH & Co, Karlsruhe 
Cryo 1C Freezing container Nalgene, USA 
Cryovials Carl-Roth GmbH & Co, Karlsruhe 
Cuvettes 10 x 4 x 45 mm Sarstedt, Nümbrecht, Germany 
Leica Confocal software (Leica) Leica Microsystems, Germany 
Microscopy glass slides 76 x 26 mm Engelbrecht, Edermunde, Germany 
Minisart syringe filters Vivascience AG, Hannover, Germany 
Neubauer chamber 0.1 mm Marienfeld, Germany 
Parafilm Peckiney, Chicago, IL, USA 
PCR Tubes Sarstedt, Nümbrecht, Germany 
Polyethylene vials 20 ml Packard, USA 
Silica G60 TLC plates Merck, Darmstadt 
sn-1,2-Diacylglycerol (DAG) Biotrak Assay 
Reagents System 
Amersham Biosciences, Freiburg 
Steritop Vacuum-driven disposable top 
filters 
Millipore, Billerica, MA, USA 
Tryptic soy agar plates with 5% sheep 
blood 
BD Biosciences, Heidelberg, Germany 
Whatman filter paper Whatman, Maidstone, UK 
X-Ray films Amersham Biosciences, Buckinghamshire, 
UK 
 
2.9. Special laboratory equipment 
Fluorescence Microplate Reader BMG Labtech, Offenburg, Germany 
Leica TCS SP confocal microscope 
equipped with a 100× oil objective 
Leica Microsystems, Wetzlar, Germany 
Microtome Techno-Med, GmbH, Bielefelt, Germany 
MATERIALS 
- 42 - 
Paraffin-Embedding-System Techno-Med, GmbH, Bielefelt, Germany 
Portable Datalogging Spectrophotometer Bachofer, Reutlingen, Germany 
Sonorex bath sonicator 
SpeedVac (Vacuum Concentrator) 
Bandelin electronic, Berlin, Germany 
Bachofer, Reutlingen, Germany 
TriCarb Liquid scintillation Perkin Elmer, USA 
 
2.10. Buffer and Solutions 
Anesthesia cocktail 
 
 
ASM lysis buffer 
10% Ketamin 2 ml 
2% Xylazin 0.5 ml 
ddH2O 10 ml 
0.1% Triton X-100 
50 mM sodium acetate pH 5.0 
Complete DMEM (Gibco) medium 500 ml DMEM (Gibco) 
10% FCS 
10 mM HEPES, pH 7.4 
2 mM L-Glutamine 
1 mM Sodium pyruvate 
100 µM non-essential amino acids 
100 units/ml Penicillin 
100 µg/ml Streptomycin 
DAG-assay Buffered Saline Solution 135 mM NaCl 
1.5 mM CaCl2 
0.5 mM MgCl2 
5.6 mM Glucose 
10 mM HEPES, pH 7.2 
DAG-assay detergent solution 7.5% N-octylglucopyranoside 
5 mM cardiolipin 
1 mM DETAPAC 
DAG-kinase diluent 1 mM DETAPAC, pH 6.6 
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DAG-kinase reaction buffer 
0.01 M imidazole/HCl 
100 mM imidazole/HCl pH 6.6 
100 mM NaCl 
25 mM MgCl2 
2 mM EDTA 
2.8 mM DTT 
5 μM ATP 
10 μCi [32P] gamma-ATP 
Freezing medium 1 ml DMSO 
2 ml FCS 
7 ml complete DMEM 
HEPES buffer 132 mM NaCl 
20 mM Hepes pH 7.4 
5 mM KCl 
1 mM CaCl2 
0.7 mM MgCl2 
0.8 mM MgSO4 
HEPES/Saline 132 mM NaCl 
20 mM HEPES, pH 7.4 
5 mM KCl 
1 mM CaCl2 
0.7 mM MgCl2 
0.8 mM MgSO4 
Mowiol 
 
 
 
 
PFA 2% 
6 g Glycerol 
2.4 g Mowiol 
6 ml ddH2O 
12 ml 0.2 M Tris-Base, pH 8.5 
0.1% DABCO 
2.5 ml PFA stock solution 
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 7.5 ml PBS 
PFA stock solution 
 
SA medium 
 
8 g PFA 
100 ml PBS 
500 ml DMEM 
1 mM HEPES, pH 7.4 
Trypsin 0.25% Trypsin 
5 mM Glucose 
1.3 mM EDTA 
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3. METHODS 
3.1. Tissue culture techniques 
3.1.1. Culture and passage of established cell lines 
EOMA cells were maintained in complete DMEM medium (see Materials) at 37°C in a 10% 
CO₂ atmosphere. Because EOMA cells grow adherent, passage of cells was achieved by 
incubation with trypsin solution to dislodge the cells from the flask wall. Prior to that, the 
cultures were examined using a light microscope, to assess the degree of confluence. Medium, 
PBS and trypsin were pre-warmed at 37°C. The cell monolayer was washed with PBS for two 
times and trypsin was added. Detachment of cells was assessed by light microscope. The 
digestion was stopped by addition of medium and the cells were centrifuged at 1500 rpm for 5 
minutes to pellet the cells. Cells were then re-suspended in medium, transferred to fresh flasks 
and kept incubated at 37°C. 
 
3.1.2. Freezing and thawing of cells 
The basic principle of successful cryo-preservation is a slow freeze and a quick thaw of cells. 
For the freezing step, DMSO was used to protect cells from ice crystal formation, which 
causes cell rupture. The freezing medium (see Materials) was prepared in advance and kept at 
4°C. Cells were collected, counted with a Neubauer chamber and re-suspended at a 
concentration of 1x106 cells/ml in freezing medium. The cell suspension was transferred in 
cryo-protective vials, which were placed at -80°C in a Cryo 1C Freezing Container overnight. 
For long-term storage, cells were placed in a liquid nitrogen storage vessel. To thaw the cells, 
the vials from liquid nitrogen storage were transferred to a water bath at 37°C.  The vials 
were moved back and forth to ensure a quick thaw. After thawing, cells were washed with 
medium to remove the DMSO, re-suspended in fresh medium, transferred to culture flasks 
and incubated at 37°C. 
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3.2. Infection experiments 
3.2.1. Preparation of Staphylococus aureus (S. aureus) 
S. aureus was stored at -80°C and plated with plastic swaps on Trypticase Soy Agar plates 
with 5% sheep blood (Becton Dickinson #254053). The plates were incubated for 16 hrs at 
37°C. Bacteria were then transferred into 40 ml 37°C pre-warmed Trypticase Soy Broth 
(TSB, Becton Dickinson #221093) in Erlenmeyer flasks at an optical density at 550 nm of 
0.2/ml (equals to 1.85 x 108 colony forming units (CFU)/ml). The bacteria were incubated for 
70 min at 37°C with shaking at 125 rpm and collected during the early logarithmic growth 
phase by centrifuging at 3000 rpm for 10 min. The bacterial pellet was washed twice in 
pre-warmed DMEM supplemented with 10 mM HEPES or phosphate buffered saline (PBS, 
137 mM NaCl, 2.7 mM KCL, 7 mM CaCl2, 0.8 mM MgSO4, 1.4 mM KH2PO4, and 6.5 mM 
Na2HPO4) and then resuspended in DMEM supplemented with 10 mM HEPES for infection 
of EOMA cells or at 5×106 CFU per 100 μL in PBS for infection of mice. Cells or mice were 
then infected within the next 10 min. 
. 
3.2.2. Infection cells with S. aureus 
To evaluate the role of S. aureus on EOMA cells, EOMA cells were plated in 24 well plates 
with cover slip at 5x104 per well with 1 ml complete DMEM or 6 well plate at 8x105 per well 
with 4 ml complete DMEM, grown for 2 days. Prior to infection, the cells were washed with 
pre-warmed PBS for 2 times and maintained in buffered DMEM medium supplemented with 
10 mM HEPES during infection and were inoculated with S. aureus at bacteria-to-host cell 
ratio of 200:1  or 10:1 (Multiplicity of infection (MOI) 200:1 or 10:1 ). Synchronous 
infection conditions and an enhanced bacterium-host cell interaction were achieved by a 
2-min centrifugation (1000 rpm) of the bacteria onto the cells. The end of the centrifugation 
was defined as the starting point of infection. If required for the experiment, we added the 
anti-oxidant Tiron or N-acetylcysteine (NAC) or the Asm inhibitor amitriptyline 20 minutes 
prior to infection as follows. 
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3.2.3. Infection mice with S. aureus 
The littermates of 8 weeks old Asm wild-type or Asm-deficient mice were infected 
intravenously with 5x106 CFU S. aureus. Between the first and the last mouse infected, we 
allowed a time interval of maximally 10 min, to exclude a change in viable counts of the 
bacteria.  
 
For pretreatment with inhibitors before infection, wt mice were injected intraperitoneally with 
10 mg/kg amitriptyline, 100 mg/kg Tiron or 100 mg/kg NAC twice daily for 2.5 days. The 
last dose was given 1 h before infection. For treatment with amitriptyline post infection, wt 
mice were injected i.p. 1 h or 2 hrs after infection with 16 mg/kg amitriptyline. Antibiotics 
were also injected i.p. 1 h after infection with 100 mg/kg methicillin (Sigma) or 100 mg/kg 
vancomycin (Sigma). The injection of methicillin or vancomycin was repeated 9 hrs after 
infection.  For mortality experiment, 10 mg/kg amitriptyline, 100 mg/kg methicillin or 100 
mg/kg vancomycin were treated twice daily in indicated group until 11 days. 
 
The mice were sacrificed at indicated infection times by cervical dislocation. The lungs were 
removed and used for CFU counting and histology as described below.  
 
3.3. Determination colony-forming units (CFUs) of S. aureus in the liver 
and spleen 
To quantify S. aureus colony forming units (CFUs) in mouse livers and spleens, the organs 
were removed after 12 hrs infection and homogenised in a loose Dounce homogenizor. The 
homogenates were lysed for 10 min in 5 mg/ml saponin (SERVA) at 37 °C to release 
intracellular bacteria. The samples were centrifuged at 3200 rpm for 10 min, resuspended in 
PBS, and plated on normal LB plates in duplicates. Bacterial CFUs were counted after the 
plates had been incubated overnight at 37 °C.  
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3.4. Immunocytochemistry 
EOMA cells were grown on coverslips, infected or uninfected for indicated time and with 
designed treatment as above. They were fixed in 2% PFA/PBS for 10 min. For intracellular 
staining, cells were permeabilized with 0.1% Triton X-100/PBS for 5 min at room 
temperature. Cells were washed again with PBS and incubated for 60 min in PBS 
supplemented with 5% FCS for all antibodies to block nonspecific binding sites. Cells were 
washed and incubated for 45 min with either anti-ZO1 IgG, anti-ZO2 IgG, anti-E-cadherin 
IgG, or an anti-Occludin IgG(see Materials). Cells were then washed three times in PBS with 
0.05% Tween-20 and incubated for an additional 45 min with Cy3-labeled donkey anti-rabbit 
antibodies. Cells were then washed again in PBS with 0.05% Tween-20. After a final PBS 
wash, cells were mounted on glass coverslips with moviol. Control experiments were 
performed with irrelevant rabbit antibodies and secondary antibodies. Control antibodies did 
not significantly bind to the cells. Cells were examined on a Leica TCS SP confocal 
microscope equipped with a 100x oil objective and images were analyzed using Leica 
Confocal software (Leica). 
 
3.5. Histology 
3.5.1. Preparation of the lung sample 
Mice were sacrificed and the lungs were subsequently removed. The left lungs were fixed in 
4% PFA for 38 hours, serially dehydrated and embedded in paraffin for sectioning at a 
thickness of 6 µm. 
 
3.5.2. Hematoxylin and eosin staining 
Lung tissue (6-mm paraffin embedded sections) were dewaxed, rehydrated and stained for 2 
min with hematoxylin and washed with water for 5 min prior to being stained with eosin for 1 
min. After a final short wash with water the sections were mounted in Mowiol and evaluated 
using a Leica TCS-SP2 microscope. 
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3.5.3. Fluorescence staining for the lungs 
The sections were then dewaxed, rehydrated and incubated in pepsin (see Materials) for 30 
min at 37°C incubator. The sections were washed and incubated for 10 min in PBS 
supplemented with 5% FCS to block nonspecific binding sites. The sections were washed 
again and incubated overnight at 4 °C with either anti-ZO1 IgG, anti-ZO2 IgG, , 
anti-E-cadherin IgG, anti-Occludin IgG, or anti-Ly-6G and Ly-6C (GR1) or FITC-labeled 
anti-Lectin antibodies, respectively. The sections were washed in PBS with 0.05% Tween-20 
and incubated for an additional 45 min with Cy3-labeled donkey anti-rabbit or anti-rat 
antibodies. The sections were then washed again in PBS with 0.05% Tween-20, once in PBS 
wash, and mounted in moviol. Control experiments were performed with irrelevant rabbit or 
goat antibodies and secondary antibodies. Control antibodies did not significantly bind to the 
lungs. The sections were examined on a Leica TCS SP confocal microscope equipped with a 
40x oil objective and images were analyzed using Leica Confocal software (Leica). 
 
3.6. Electron Spin Resonance Detection of Endothelial O2.- 
ROS production was measured by electron spin resonance (ESR), as we described previously 
(Abais et al 2014, Li et al 2013b). 2x105 endothelial Cells were infected with S.aureus for the 
indicated time, the medium removed, the cells scraped into 20 mM HEPES (PH 7.5), 1 mM 
EDTA, and 255 mM sucrose and shock frozen in liquid nitrogen. Proteins were isolated and 
resuspended with modified Krebs-HEPES buffer containing deferoximine (100 μM, Sigma) 
and diethyldithiocarbamate (5 μM, Sigma). A spin trap, 
1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine (CMH, Noxygen, Elzach, 
Germany) (1 mM final concentration), was then added to the mixture in the presence or 
absence of manganese-dependent superoxide dismutase (SOD, 200 U/mL; Sigma, St. Louis, 
MO). The mixture was loaded into glass capillaries and immediately kinetically analyzed for 
O2.- production for 10 min. The SOD-inhibited fraction of the signal was used to calibrate the 
system. The ESR settings were as follows: biofield, 3,350; field sweep, 60 G; microwave 
frequency, 9.78 GHz; microwave power, 20 mW; modulation amplitude, 3 G; points of 
resolution, 4,096; receiver gain, 100; and kinetic time, 10 min. The ESR signal strength was 
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recorded in arbitrary units and the final results were expressed as the fold changes compared 
to the control as described (Xu et al 2013). 
 
3.7. Asm activity assay 
The activity of Asm was measured as the consumption of radioactive [14C]-sphingomyelin to 
ceramide and [14C]-phophorylcholine. To this end, 8x105 EOMA cells were infected with S. 
aureus for indicated times, washed, lysed in 300 μl/sample ice-cold ASM-lysis buffer (see 
Materials). The cells were removed from the plate, transferred into eppendorf tubes and 
immediately sonicated three times (3x10 s). Since [14C]-sphingomyelin is insoluble in water, 
it was first dried by SpeedVac centrifugation and solubilized into micelles in ASM-lysis 
buffer, using a bath sonicator for 10 min. Cell lysates were incubated with 0.05 μCi per 
sample [14C]-labeled sphingomyelin (2 GBq/mmol) for 30 min at 37°C on a thermomixer. 
Lipids were extracted by addition of 1 ml/sample of CHCl3:CH3OH (2:1, v/v), followed by 
vigorous vortexing for 30 sec and centrifugation at 14000 rpm for 5 min. An aliquot (300 μl) 
of the aqueous phase was applied for liquid scintillation counting. Hydrolysis of 
[14C]-sphingomyelin by Asm results in release of [14C]-choline chloride into the aqueous 
phase, whereas ceramide and unreacted [14C]-sphingomyelin remain in the organic phase. 
Therefore, the release of [14C]-choline chloride (pmol/105 cells/h) serves to determine the 
activity of the Asm. 
 
3.8. Ceramide measurement by DAG kinase assay 
3.8.1. Lipid extraction and enzymatic reaction 
Cellular ceramide was measured by DAG kinase assay, in which ceramide is converted to a 
quantifiable product (ceramide-1-phosphate) by transfer of [32P]-phosphate from [32P]-gamma 
ATP to ceramide. To this end, cells were infected as above, first extracted in 
CHCl3:CH3OH:1N HCl (100:100:1, v/v/v). The resulting biphasic mixture is composed of a 
lower lipid-containing organic phase, and an upper aqueous phase. An aliquot of the lower 
organic phase was collected and dried by evaporation of the chloroform in a SpeedVac. The 
dried lipids were solubilized in 20 µl of DAG-assay detergent solution (see Materials) and 
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sonicated for 10 min in a bath sonicator, and 50 µl of DAG-kinase reaction buffer (see 
Materials), and 10 µl of diluted enzyme (dilution 1:1, v/v in DAG-kinase diluent) (see 
Materials) were added. The kinase reaction was performed for 30 min at room temperature on 
a thermomixer. The samples were re-extracted in 1 ml/sample CHCl3:CH3OH:1N HCl 
(100:100:1, v/v/v), 170 µl/sample DAG-assay Buffered Saline Solution (see Materials) and 30 
µl of a 100 mM EDTA solution, followed by vortexing. The resulting upper phase was 
removed, and the lower organic phase was again concentrated by SpeedVac centrifugation. 
The dried lipids were dissolved in 20 µl/sample CHCl3:CH3OH (1:1, v/v). 
 
3.8.2. Separation of lipids by Thin Layer Chromatography (TLC) 
Lipids were separated on a Silica G60 TLC plate. A solvent system of 
CHCl3:CH3COCH3:CH3OH:CH3COOH:H2O (10:4:3:2:1, v/v/v v/v) was added to the TLC 
chamber, and was allowed to saturate the atmosphere for 1 h by using a sheet of Whatman 
filter paper. The silica plates were loaded with the solubilized lipids, placed into the TLC 
chamber and the solvent front was allowed to migrate to the top of the plate. The plate was 
then removed, air dried for 45 min and exposed to X-ray films for 24 hours. Ceramide-spots 
were identified by comigration with a C16-ceramide standard, and incorporation of 32P into 
ceramide was quantified by liquid scintillation counting. Comparison with a standard curve 
using C16-ceramide permitted the determination of ceramide amounts. 
 
3.9. Evans blue microvascular permeability analysis of lung edema 
To assess vascular leakage, 4% Evans blue dye (20 mg/kg) was injected into the external 
jugular vein 30 min before the termination of the experiment as described (Moitra et al 2007). 
Evans blue dye has a very high binding affinity for serum albumin. When the vascular barrier 
in the lung is compromised, albumin-bound Evans blue moves into the lung parenchyma. The 
lungs were perfused free of blood with phosphate-buffered saline via right heart, removed, 
dried, weighed, and was homogenized in PBS (1 ml/100 μg tissue), incubated with 2 volumes 
of formamide to extract the dye (18 h, 60°C), and centrifuged at 5,000 × g for 30 minutes, and 
the optical density of the supernatant was determined at 620 nm and 740 nm with a 
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fluorescence microplate reader (BMG Labtech, Offenburg, Germany). The extravasated EB 
concentration in lung homogenate was calculated against a standard curve and was expressed 
as micrograms of Evans blue dye per gram of lung.  
 
3.10. DNA techniques  
3.10.1. DNA isolation 
3.10.1.1 DNA isolation from mouse tails 
For genotyping of wt and Asm-deficient mice, app. 1-2 mm of mouse tail was cut and placed 
into 80 µl Tissue Lysis Buffer (TLB) (see Materials). The samples were incubated at 56°C 
overnight and diluted with 800 µl autoclaved ddH2O. 
 
3.10.1.2 DNA isolation from cell lines 
To test cultured cell lines for the presence of Mycoplasma, 5 x105 cells/sample were pelleted 
and re-suspended into 50 µl TLB. The samples were incubated at 56°C for 3 h and boiled at 
95°C for 10 min. The volumes were then raised to 100 µl with autoclaved ddH2O. 
 
3.10.2. Polymerase Chain Reaction (PCR)  
3.10.2.1 Asm PCR 
For the detection of Asm by PCR, 1 µl of overnight tail digest (see 3.10.1.1.) was added to 1.2 
µl 10 x PCR Buffer, 2.5 mM MgCl2, 1µl dNTP mix 5 units/ml Taq Polymerase and 0.1 µl 
each of primers Asm-PA1-2, Asm-PA2-2 an Asm-PS-2 in 0.2 ml PCR tubes. The temperature 
of the lid of the PCR machine was raised to 104°C and the temperature of the PCR block was 
raised to 96°C for 17 min, after which the following cycle was carried out 35 times: 
Denaturation: 95°C for 1 min 
Annealing: 58°C for 1 min 
Elongation: 72°C for 1 min 45 sec  
After the last cycle, the PCR block remained at 72°C for 5 min, after which the samples were 
placed at 4°C. 
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3.10.2.2 Mycoplasma PCR 
For the identification of mycoplasma by PCR, 1 µl of cell digest (see 3.10.1.2.) was added to 
2.5 µl 10 x PCR Buffer, 4.1 mM MgCl2, 0.5 µl dNTP mix 1.25 units/ml Taq Polymerase and 
0.25 each of primers P1 and P4 in 0.2 ml PCR tubes. The temperature of the lid of the PCR 
machine was raised to 104°C and the temperature of the PCR block was raised to 96°C for 17 
min, after which the following cycle was carried out 25 times: 
Denaturation: 95°C for 1 min 
Annealing: 60°C for 1 min 
Elongation: 72°C for 1 min 30 sec 
After the last cycle, the PCR block remained at 72°C for 7 min, after which the samples were 
placed at 4°C. 
 
3.10.3. Agarose gel electrophoresis 
PCR products were analysed on 1% agarose gels. Agarose was poured in TBE buffer (see 
Materials) that contained 0.01 µg/ml ethidium bromide. The samples (15 µl) were loaded on 
the gel along with 0.1 µg/µl of a 100-bp-standard. The gel was run under 5 V/cm current. 
Visualization of the DNA fragments was performed under UV-light. 
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4. RESULTS 
4.1. Asm deficiency prevent S. aureus-induced lung edema 
4.1.1. Asm deficiency mitigates pulmonary edema upon S. aureus infection  
To investigate whether activation of Asm is required in the in vivo development of lung 
edema upon S. aureus infection, we systemically infected C57BL/6 wild type (wt) and 
Asm-deficient mice with S. aureus for various time periods. To date, a large amount of 
studies indicated that degradation of tight junctional proteins leads to microvascular leakage 
and finally pulmonary edema (Corada et al 1999, Jang et al 2011). To determine pulmonary 
edema, we injected Evans blue dye into the mice 30 min before sacrificing the mice to 
analyze lung edema. The studies revealed massive leakage of Evans blue dye into the lungs of 
wt mice but almost no leakage into the lungs of Asm-deficient mice upon systemic infection 
with a clinical S. aureus strain (Figure 4.1.1.A-1.) or the S. aureus Newman strain (Figure 
4.1.1.A-2.). Moreover, hematoxylin and eosin (H&A) staining of the lungs demonstrated that 
the clinical S. aureus infection induced massive lung edema in a time-dependent manner in wt 
mice, a finding that was absent or much less pronounced in Asm-deficient mice (Figure 
4.1.1.B.). 
 
A-1                                     A-2 
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Figure 4.1.1. Effect of Asm deficiency on pulmonary edema upon S. aureus infection 
 
(A) Wild-type (wt) and Asm-deficient mice were infected with a clinical S. aureus strain (A-1) or the 
S. aureus Newman strain (A-2) for the indicated time periods. Evans blue dye was injected 30 min 
before sacrificing the mice, flushing the lung via the right heart to remove intravascular Evans Blue 
and removal of the lungs. The amount of dye leaking into the lung tissue was quantified. Shown is the 
number (mean ± SD) of the concentration of Evans blue dye in the lungs from each 5 wildtype and 
Asm-deficient mice. *, significant differences between uninfected mice and infected mice; Δ, 
significant differences between infected wild-type mice and Asm-deficient mice (all P<0.05; t-test).  
 (B) Wild-type and Asm-deficient mice were infected with S. aureus for the indicated time periods. 
They were sacrificed and lung sections were stained with H&E and analyzed by light microscopy for 
the detection of lung edema. Scale bar is 100 µM (magnification, 63×). Representative images from 
three independent experiments are shown. 
 
4.1.2. Asm deficiency prevents neutrophil trafficking to the lung 
Neutrophils have a pivotal role in the defense against bacterial infections. However, 
overwhelming activation of neutrophils is known to elicit tissue damage and contribute to 
severe sepsis (Adams et al 2001, Guo et al 2002, Windsor et al 1993). 
 
This led us to examine whether Asm expression is also required for pulmonary neutrophil 
trafficking during systemic S. aureus infection. To this end, we stained lung sections from 
infected wt and Asm-deficient mice with anti-GR1 antibodies, a neutrophil marker. Confocal 
fluorescence microscopy studies reveal that S. aureus infection induced excessive neutrophil 
trafficking to the lung in a time-dependent manner in wild type mice (Figure 4.1.2.A.). 
However, neutrophil trafficking into the lung tissue was reduced markedly in Asm-deficient 
mice after infection (Figure 4.1.2.A.). Quantitative analysis of neutrophils demonstrates that 
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Asm is an important regulator for S. aureus–induced neutrophil trafficking to the lung during 
S. aureus sepsis (Figure 4.1.2.B.). 
     A 
 
 
     B 
Figure 4.1.2. Effect of Asm deficiency on neutrophil trafficking induced by S. aureus infection 
 
(A and B) For determination of neutrophil trafficking, wt and Asm-deficient mice were left uninfected 
or were infected with a clinical S. aureus strain for different time points. Lung sections were stained 
with Cy3-labeled anti-GR1 antibodies and analyzed by fluorescence microscopy. Scale bar is 50 µM. 
Shown are representative images from three independent experiments. Cells staining positive for GR1, 
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a neutrophil marker, were quantified by analysis of 50 fields per group. Shown is the number (mean ± 
SD) of GR1-positive cells per field of 63x magnification. *, significant differences between uninfected 
mice and infected mice; Δ, significant differences between infected wild-type mice and Asm-deficient 
mice (all P<0.05; t-test).  
 
Taken together, these findings indicate that Asm plays a key role in the development of 
pulmonary edema induced by systemic infection with S. aureus. Asm deficiency prevents the 
development of lung injury during infection. 
 
4.2. Infection of endothelial cells with S. aureus activates  
Asm and leads to the production of ROS in a positive feedback loop 
4.2.1. S. aureus infection rapidly activates the Asm 
To test whether systemic S. aureus infections activates Asm, we infected murine endothelial 
(EOMA) cells with a clinical S. aureus strain (MOI 200:1) and measured Asm activity. S. 
aureus infection induced a marked activation of the Asm (Figure 4.2.1.A.). Additionally, the 
well-characterized S. aureus sepsis strain Newman was tested to determine whether systemic 
S. aureus infections induced Asm activation is a general phenomenon. Following infection 
with S. aureus sepsis strain Newman (MOI 200:1), the kinetics of Asm activation showed a 
similar pattern in EOMA cells than after infection with the clinical S. aureus strain (Figure 
4.2.1.B.).  
A                                            B 
                         
 
Figure 4.2.1. S. aureus infection activates Asm 
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Asm activity were measured in EOMA cells after infection with a clinical S. aureus strain (MOI 
200:1) (A) or the S. aureus Newman strain (MOI 200:1) (B) for 0, 2, 5, or 10 min. Results show the 
mean ± SD of three independent experiments. *, significant differences compared to uninfected 
control mice (P<0.05, t-test).  
 
4.2.2. S. aureus infection also induces a marked formation of the ceramide    
As we know Asm is one of the most important sphingomyelinase which hydrolyzes 
sphingomyelin to ceramide and phosphorylcholine. To further define whether systemic S. 
aureus infections induces the formation of ceramide, which is the product of Asm activity, we 
infected EOMA cells with a clinical S. aureus strain or the S. aureus Newman stain (MOI 
200:1) and measured ceramide production. The results showed a rapid release of ceramide 
upon these two S. aureus strains infection (Figure 4.2.2.A. and B.). 
 
A                                              B 
 
              
 
Figure 4.2.2. S. aureus infection induced ceramide release  
 
Ceramide concentrations were measured in EOMA cells after infection with a clinical S. aureus strain 
(MOI 200:1) (A) or the S. aureus Newman strain (MOI 200:1) (B) for 0, 2, 5, or 10 min. Results show 
the mean ± SD of three independent experiments. *, significant differences compared to uninfected 
control mice (P<0.05, t-test).  
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4.2.3. S. aureus infection induces a rapid production of the ROS     
Amitriptyline is a tricyclic antidepressant (TCA). It is the most widely used TCA and is 
efficacious for the treatment of depression (Barbui et al 2001, Garattini et al 1998). Several 
publications indicated that amitriptyline works as a functional Asm inhibitor and for instance 
reduces the pulmonary accumulation of ceramide in cystic fibrosis (Becker et al 2010b, 
Grassmé et al 1997, Kornhuber et al 2008, Kornhuber et al 2010, Kornhuber et al 2011, 
Teichgraber et al 2008).  
 
ROS have been shown for a long time to play a critical role in host-pathogen interactions 
(Djaldetti et al 2002, Karupiah et al 2000, Moore et al 2012, Pai et al 2012, Wyllie et al 2011). 
Previous studies showed a critical role of the Asm in ROS production in macrophages and 
hepatocytes (Hatanaka et al 1998, Pai et al 2012, Reinehr et al 2005, Zhang et al 2007). To 
investigate whether S. aureus infection induces ROS production and whether S. 
aureus-induced ROS production depends on Asm, we infected EOMA cells with two 
different strains (MOI 200:1)  and analyzed the production of oxygen radicals. The results 
showed that S. aureus infection induced a rapid production of ROS in EOMA cells (Figure 
4.2.3.A. and B.), which was prevented by pre-incubation with the functional Asm inhibitor 
amitriptyline (Ami) (Figure 4.2.3.A. and B.) indicating that the production of ROS after 
infection with S. aureus requires the activation of Asm. 
 
A                                             B 
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Figure 4.2.3. S. aureus-induced ROS, a process that depends on the Asm 
 
EOMA cells were preincubated with amitriptyline (20 µM) for 20 min and then infected with a 
clinical S. aureus strain (MOI 200:1) (A) or the S. aureus Newman strain (MOI 200:1) (B) for 7.5 min. 
The production of ROS was quantified by electron spin resonance. Relative O2- levels were used to 
indicate ROS accumulation. Data for panels A and B are mean ± SD of four independent experiments. 
Significant differences between infected and non-infected controls were determined by t-test and are 
indicated by asterisk (* P<0.05). Significant differences between untreated samples and 
amitriptyline-treated samples were determined by t-test and are indicated by delta (Δ P<0.05). 
 
4.2.4. Infection of endothelial cells with S. aureus activates Asm and leads to the 
production of ROS in a positive feedback loop 
To further define the interaction of S. aureus-induced Asm activation and ROS production, 
we pre-incubated of EOMA cells with the functional Asm inhibitor amitriptyline (Ami) or 
with antioxidant Tiron or NAC for 20 min, and infected EOMA cells with a clinical S. aureus 
strain at a lower multiplicity of infection (MOI= 10:1) for another 20 min and determined 
Asm activity and ROS production. The results revealed a similar but slightly delayed time 
course of Asm activation (Figure 4.2.4.A.) and ROS release (Figure 4.2.4.B.). Pre-incubation 
of EOMA cells with the antioxidants Tiron or N-acetylcysteine (NAC) reduced Asm 
activation by S. aureus (Figure 4.2.4.A.). Pre-incubation of EOMA cells with the functional 
Asm inhibitor amitriptyline (Ami) or with Tiron or NAC also inhibited ROS release (Figure 
4.2.4.B.) suggesting a positive feedback loop of S. aureus–induced Asm activation and ROS 
release.  
 
A                                       B 
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Figure 4.2.4. S. aureus-induced Asm activation and ROS production form a positive feedback 
loop  
 
EOMA cells were pre-incubated with Ami or NAC or Tiron (20 µM) for 20 min and then infected 
with a clinical S. aureus strain (MOI 10:1)  for 20 min. Ceramide concentrations (A)  and ROS 
production (B) were measured. Data for panels A and B are mean ± SD of four independent 
experiments. Significant differences between infected and non-infected controls were determined by 
t-test and are indicated by asterisk (* P<0.05). Significant differences between untreated samples and 
amitriptyline-treated samples were determined by t-test and are indicated by delta (Δ P<0.05). 
 
4.3. S. aureus induces degradation of junctional proteins via the 
Asm/ceramide system 
4.3.1. Asm deficiency prevents degradation of junctional proteins upon S. aureus 
infection in vivo          
During a severe S. aureus infection, the bacteria and their toxins may spread in the 
bloodstream and affect the integrity of endothelial cells, thereby resulting in increased 
vascular permeability (Hocke et al 2006, Seeger et al 1990). It is well documented that 
endothelial activation plays a major role in the cellular immune response to sepsis (Aird 2003, 
Ait-Oufella et al 2010, Boos et al 2006). 
 
To gain insight into the mechanism by which Asm and ceramide mediate endothelial 
dysfunction and lung edema after S. aureus infection, we determined whether systemic 
infection with S. aureus induces the breakdown of junctional proteins in pulmonary 
endothelial cells in vivo, and, if so, whether this process depends on the Asm/ceramide 
system. To this end, we systemically infected wt and Asm-deficient mice with 5x106 a clinical 
S. aureus strain. We then obtained lung sections and stained them with Cy3-labeled 
antibodies against ZO1, ZO2, Occludin, or E-cadherin. Confocal microscopy showed that 
infection with S. aureus induces dramatic degradation of ZO1, ZO2, Occludin, and 
E-cadherin junctional proteins in a time-dependent manner in endothelial cells from blood 
vessels in wt lungs but not in endothelial cells from the lungs of Asm-deficient mice (Figure 
4.3.1.A-D.). Thus, the disruption of junctional proteins, which is caused by S. aureus 
infection in vivo, requires functional Asm. 
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Co-stainings of lung sections with Cy3-coupled antibodies against junctional proteins and 
FITC isolectin B4, which is a marker for endothelial cells, confirmed that junctional proteins 
are only degraded in lung endothelial cells of wt mice upon infection with S. aureus, but not 
in Asm-deficient endothelial cells (Figure 4.3.1.E-H.). 
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Figure 4.3.1. Effect of Asm deficiency on degradation of junctional proteins upon S. aureus 
infection in vivo 
 
Wild-type and Asm-deficient mice were left uninfected or were infected with S. aureus for different 
time points. The lungs were removed, fixed, dehydrated and embedded in paraffin for sectioning at a 
thickness of 6 µm. The lung sections were stained with Cy3-labeled anti-ZO1 (A and E), anti-ZO2 (B 
and F), anti-Occludin (C and G) or anti-E-cadherin (D and H) antibodies (magnification, 40×). 
Representative fluorescence images from three independent experiments are shown (original image 
and an area of interest [AOI]). Scale bar is 10 µM. 
 
4.3.2. Asm and ROS are necessary to degradation of junctional proteins induced by S. 
aureus infection in vivo 
In order to further confirm that Asm is involved in regulating junctional proteins degradation 
upon S. aureus infection in vivo and whether junctional proteins degradation presupposes the 
production of ROS, we pretreated wt mice with intraperitoneal injections of amitriptyline or 
Tiron and then infected them with a clinical S. aureus strain. Confocal microscopy analysis 
demonstrated that the inhibition of Asm or ROS also protects junctional proteins in lung 
endothelial cells from degradation after systemic S. aureus infection in vivo (Figure 
4.3.2.A-D.).   
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Figure 4.3.2. Inhibition of Asm and ROS prevents S. aureus-induced degradation of junctional 
proteins in vivo 
 
Wild type C57BL/6J mice were pretreated with 10 mg/kg amitriptyline, 100 mg/kg Tiron or 100 
mg/kg NAC by intraperitoneal injection, twice daily for 2.5 days, and then infected with S. aureus for 
12 hrs. The lungs were removed, fixed, dehydrated and embedded in paraffin for sectioning at a 
thickness of 6 µm. The lung sections were stained with Cy3-labeled anti-ZO1 (A), anti-ZO2 (B), 
anti-Occludin (C) or anti-E-cadherin (D) antibodies (magnification, 40×). Representative fluorescence 
images from three independent experiments are shown (original image and an area of interest [AOI]). 
Scale bar is 10 µM. 
 
4.3.3. Asm and ROS are necessary to degradation of junctional proteins induced by S. 
aureus infection in vitro 
To further confirm the degradation of junctional proteins is a consequence of Asm activation 
and ROS production, we pre-incubated EOMA cells with 20 µM amitriptyline, 10 mM Tiron 
or 10 mM NAC before infection with a clinical S. aureus strain (MOI 10:1). We found that 
inhibition of Asm or ROS protects junctional proteins from degradation after S. aureus 
infection in the EOMA cells (Figure 4.3.3.).    
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Figure 4.3.3. Inhibition of Asm and ROS prevents S. aureus-induced degradation of junctional 
proteins in vitro 
 
EOMA cells were pretreated for 20 min with amitriptyline (20 µM), Tiron (10 mM) or NAC (10 mM) 
before being infected with a clinical S. aureus strain (MOI 10:1) for 2hrs. Immunoflourescence 
stainings were performed with antibodies against ZO1, ZO2, Occludin, or E-cadherin for 
determination of the degradation of these junctional proteins. The presented pictures are representative 
of the results of at least three independent experiments (magnification, 40×). Scale bar is 25 µM. 
 
The data presented above demonstrate that S. aureus infection leads to the degradation of 
tight junctional proteins in vitro and in vivo. Genetic deficiency or pharmacological inhibition 
of Asm prevents S. aureus-induced degradation of junctional proteins. Moreover, inhibition of 
ROS also protects junctional proteins from degradation. Collectively, these findings indicate 
that Asm mediates the S. aureus–induced breakdown of junctional proteins by ROS. 
 
4.4. Pharmacologic inhibition of Asm or ROS before systemic infection 
with S. aureus prevents lung edema 
 
4.4.1. Pretreatment with amitriptyline, Tiron or NAC alleviates pulmonary edema upon 
S. aureus infection  
To test the significance of the pathway from the Asm via ROS to the degradation of junctional 
proteins for the development of lung edema, we treated wt mice with intraperitoneal 
injections of amitriptyline, Tiron or NAC before systemic infection with a clinical S. aureus 
strain and then measured lung edema. S. aureus infection induced severe lung edema (Figure 
4.4.1.A. and B.), events that were prevented by pretreatment with amitriptyline, Tiron or 
NAC (Figure 4.4.1.A. and B.). These findings show that lung edema induced by S. aureus 
via the pathway through Asm and ROS can be prevented by pretreatment with pharmacologic 
inhibitors of this pathway. 
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Figure 4.4.1. Effect of pharmacological Asm inhibition and neutralization of ROS on pulmonary 
edema upon S. aureus infection 
 
Wild-type mice were pretreated by intraperitoneal injection of 10 mg/kg amitriptyline, 100 mg/kg 
Tiron or 100 mg/kg NAC, twice daily for 2.5 days. Mice were infected with S. aureus for 12 hrs. Lung 
edema was determined by extravasation of Evans Blue (A) and by staining with H&E (scale bar is 100 
µM, magnification, 20×) (B). Representative images from three independent experiments are shown. 
*, significant differences between uninfected and infected samples; Δ, significant differences between 
treated and untreated samples (all P<0.05, t-test). 
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4.4.2. Pretreatment with amitriptyline, Tiron or NAC decreases neutrophil trafficking 
into the lung               
Next, we tested whether Asm and ROS play an important role on neutrophil trafficking to the 
lung induced by S. aureus infection as suggested by their marked effect on the integrity of 
junctional proteins and lung edema. To this end, we treated wt mice with intraperitoneal 
injections of amitriptyline, Tiron or NAC before systemic infection with a clinical S. aureus 
strain and then measured neutrophil influx. The results revealed that pretreatment with 
amitriptyline, Tiron or NAC prevented influx of neutrophils into the lung (Figure 4.4.2.A. 
and B.). This data indicates that Asm and ROS facilitate neutrophil trafficking following into 
lung tissue upon S. aureus infection. 
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Figure 4.4.2. Effect of amitriptyline, Tiron or NAC on neutrophil trafficking into lung tissue 
induced by S .aureus infection 
 
Wild-type mice were pretreated by intraperitoneal injection of 10 mg/kg amitriptyline, or 100 mg/kg 
Tiron or 100 mg/kg NAC twice daily for 2.5 days. Mice were infected with S. aureus for 12 hrs. 
Neutrophil emigration was determined by staining of lung sections with Cy3-labeled anti-GR1 
antibody (scale bar is 50 µM) followed by fluorescence microscopy (A). Shown are representative 
images from three independent experiments. Neutrophil trafficking was quantified by analysis of 50 
fields per group (B). Displayed is the average of GR1-positive cells per field of 63x magnification. *, 
significant differences between uninfected and infected samples; Δ, significant differences between 
treated and untreated samples (all P<0.05, t-test). 
 
The results from 4.4.1 and 4.4.2 indicate pharmacologic inhibition of Asm or ROS before 
systemic infection with S. aureus prevents lung edema and influx of neutrophils into the lung.  
 
4.5. Treatment of already septic mice with amitriptyline prevents the 
development of lung edema 
4.5.1. Treatment with amitriptyline 1 hr or 2 hrs post S. aureus-infection reduces 
pulmonary edema             
The finding that both Asm-deficiency and pre-incubation with the Asm inhibitor amitriptyline 
protect mice from lung edema induced by S. aureus infection led us question whether the 
administration of amitriptyline reduces the severity of pulmonary edema in mice that were 
already infected with S. aureus. If so, amitriptyline administration might be a clinically 
relevant therapeutic option for the treatment of S. aureus–induced pulmonary edema. To this 
end, we infected wt mice with a clinical S. aureus strain and treated them with amitriptyline 1 
or 2 hrs later. Twelve hours after infection, the mice were sacrificed and Evans Blue 
extravasation was determined or lung sections were stained with H&E. As shown in Figure 
4.5.1.A. and B., treatment with amitriptyline reduced the severity of pulmonary edema even 
after the onset of systemic infection with S. aureus. 
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Figure 4.5.1. Amitriptyline treatment prevents lung edema in S. aureus-infected mice even after 
onset of the systemic infection 
 
Wild-type mice were infected with S. aureus. 1 h or 2 hrs later they were i.p. injected with 16 mg/kg 
amitriptyline. The mice were sacrificed 12 hrs after infection. Lung edema was determined by 
extravasation of Evans Blue (A) and by staining with H&E (scale bar is 100 µM, magnification, 20×) 
(B). Panel A shows the mean ± SD from 4 mice. Images in B are representative from three 
independent experiments. *, significant differences between uninfected and infected samples; Δ, 
significant differences between treated and untreated samples (all P<0.05, t-test). 
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4.5.2. Treatment with amitriptyline 1 hr or 2 hrs after S. aureus-infection prevents 
degradation of junctional proteins 
To determine whether pharmaceutical blockade of Asm by amitriptyline even after infection 
with S. aureus also protects the mice from degradation of junctional proteins in vivo, 
wild-type C57BL/6J mice were infected with a clinical S. aureus strain. The mice were 
treated with i.p. injection of 16 mg/kg amitriptyline 1 hr or 2 hrs after infection, respectively. 
The mice were sacrificed 12 hrs after infection and the lung sections were stained with 
anti-ZO1, anti-ZO2, anti-Occludin or anti-E-cadherin antibodies and analyzed by confocal 
fluorescence microscopy. The results showed amitriptyline-treatment reduced the degradation 
of junctional proteins even when the drug was applied 1 hr or 2 hrs post infection with S. 
aureus (Figure 4.5.2. A-D.).  
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Figure 4.5.2. Amitriptyline treatment prevents degradation of junctional proteins even if 
administered after S. aureus infection 
 
Wild-type mice were infected with S. aureus and were treated 1 h or 2 hrs after infection with i.p. 
amitriptyline. Twelve hours after infection, the mice were sacrificed. Lung sections were stained with 
Cy3-labeled antibodies against ZO1 (A), ZO2 (B), Occludin (C) or E-cadherin (D). Images were 
obtained by confocal microscopy and are representative of three independent experiments 
(magnification, 40×). The original image and an area of interest (AO1) are shown. Scale bar is 10 µM. 
 
4.5.3. Treatment with amitriptyline 1hr or 2 hrs after infection prevents neutrophil 
trafficking into the lung tissue  
To determine whether pharmacological inhibition of Asm with amitriptyline also reduces 
neutrophil trafficking after infection of mice with S. aureus, wild-type C57BL/6J mice were 
infected with S. aureus. Again, the mice received 16 mg/kg amitriptyline by i.p. injected 1 hr 
or 2 hrs after infection. The mice were sacrificed 12 hrs after infection and the lung sections 
were stained with anti-GR1 antibody. The results demonstrated that amitriptyline treatment 
reduced pulmonary influx of neutrophils even if injected 1 hr or 2 hrs after infection, which 
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confirms that Asm play an important role in S. aureus-induced neutrophil trafficking (Figure 
4.5.3. A. and B.). 
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Figure 4.5.3. Amitriptyline treatment reduces S. aureus-induced neutrophil trafficking  
 
Wild-type mice were infected with S. aureus for 1 hr or 2 hrs, and then treated with i.p. injection of 16 
mg/kg amitriptyline. The mice were sacrificed 12 hrs after infection and the lungs were removed, 
fixed, dehydrated and embedded. The lung sections were stained with Cy3-labeled anti-GR1 antibody 
(scale bar is 50 µM, magnification, 63×) (A). Representative images from three independent 
experiments are shown. The average number of GR1-positive cells per field of 63x magnification was 
quantified by analysis of 50 fields per group (B). Data are shown as mean ± SD, n = 3. *, significant 
differences between uninfected and infected samples; Δ, significant differences between treated and 
untreated samples (all P<0.05, t-test). 
 
This indicates that amitriptyline treatment after systemic infection with S. aureus protects 
junctional proteins degradation and reduces pulmonary influx of neutrophils, finally 
preventing pulmonary edema. Thus, amitriptyline might be a novel therapy to S. 
aureus-induced sepsis. 
 
4.6. The combination of amitriptyline and antibiotics in the very early time 
can be a novel therapy to S. aureus-induced sepsis 
4.6.1. The combination of amitriptyline and antibiotics contributes to bacteria killing  
Sepsis remains a challenge for intensive care physicians and is one of the leading causes of 
death nowadays. Although improvements in supportive care of patients with sepsis (eg, more 
effective and less damaging mechanical ventilation, improved fluid resuscitation, and 
broad-spectrum antibiotic coverage) have improved survival rates, sepsis remains a condition 
with high mortality ranging from 20% to 50% of severely affected patients (Creamer et al 
2012, Kanafani et al 2009, Moore et al 2011).  
 
Clinically, treating S. aureus sepsis with antibiotics often achieves only limited success, and 
severe lung edema often still develops even with appropriate antibiotic treatment (Kanafani et 
al 2009, Moore et al 2011, Moore et al 2012). Thus, with the aim of developing novel 
efficient therapeutic approaches to the treatment of S. aureus–induced sepsis and lung edema, 
we examined the effect of a combination of amitriptyline and antibiotics on bacterial killing 
and lung edema after systemic S. aureus infection. To this end, we infected wt mice with a 
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clinical S. aureus strain or the S. aureus Newman strain. One hour after infection with the 
incidence of first clinical symptoms, amitriptyline (Ami) or methicillin (Methi) or 
vancomycin (Vanco) or a combination of amitriptyline and either methicillin or vancomycin 
were injected. The injection of methicillin or vancomycin was repeated after 9 hrs. Control 
mice were left uninfected. The mice were sacrificed 12 hrs after infection, and bacterial 
numbers were determined in liver and spleen. Only antibiotics alone or in combination with 
amitriptyline kill bacteria in liver and spleen (Figure 4.6.1. A-B.). Treatment with 
amitriptyline alone can’t kill bacteria and even shows more bacterial numbers in liver and 
spleen compared to untreated wt mice after infection (Figure 4.6.1. A-B.). 
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Figure 4.6.1. Effect of the combination of amitriptyline and antibiotics on bacteria killing 
 
Wild-type mice were infected with a clinical S. aureus strain (A) or the S. aureus Newman strain (B). 
They were then left untreated; treated with an i.p. injection of amitriptyline (16 mg/kg) 1 h after 
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infection; treated with either methicillin or vancomycin (both 100 mg/kg) 1 h and 9 hrs after infection; 
or treated with the combination of amitriptyline and methicillin or vancomycin. The mice were 
sacrificed 12 hrs after infection. The liver and spleen were removed, homogenized, and lysed in 
saponin for the quantification of intracellular and extracellular bacteria (CFU) on lysogeny broth (LB) 
plates. Data shown are mean ± SD of three independent experiments. *, significant differences 
between uninfected and infected samples; Δ, significant differences between treated and untreated 
samples (P<0.05, t-test). 
 
4.6.2. The combination of amitriptyline and antibiotics inhibits neutrophil trafficking 
into the lung 
To define the effect of the combination of amitriptyline with antibiotics on neutrophil 
trafficking into the lung upon S. aureus infection, we infected wt mice with a clinical S. 
aureus strain or the S. aureus Newman strain. One hour after infection with the incidence of 
first clinical symptoms, amitriptyline or methicillin or vancomycin or a combination of 
amitriptyline and either methicillin or vancomycin were injected. The injection of methicillin 
or vancomycin was repeated after 9 hrs. Control mice were left uninfected. The mice were 
sacrificed 12 hrs after infection and the left lungs were removed. Obtained lung sections were 
stained with anti-GR1 antibody and analysed by confocal fluorescence microscopy. The 
results showed S. aureus-induced neutrophil trafficking into the lung is abrogated by 
treatment with amitriptyline alone or combining with antibiotics, but not treatment with 
methicillin or vancomycin alone (Figure 4.6.2. A-B.). 
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Figure 4.6.2. The combination of amitriptyline and antibiotics abrogates S. aureus-induced 
neutrophil trafficking into the lung 
 
Wild-type mice were infected with a clinical S. aureus strain (A) or the S. aureus Newman strain (B). 
They were then left untreated; treated with an i.p. injection of amitriptyline (16 mg/kg) 1 h after 
infection; treated with either methicillin or vancomycin (both 100 mg/kg) 1 h and 9 hrs after infection; 
or treated with the combination of amitriptyline and methicillin or vancomycin. 12 hrs after infection, 
four mice per group were sacrificed and the left lungs were removed, fixed, dehydrated and embedded 
in paraffin for sectioning at a thickness of 6 µm. The lung sections were stained with Cy3-labeled 
anti-GR1 antibody (scale bar is 50 µM, magnification, 63×). Representative fluorescence images from 
three independent experiments are shown. 
 
4.6.3. The combination of amitriptyline and antibiotics protects mice from tight 
junctional proteins degradation after S. aureus infection 
To determine the effect of the combination of amitriptyline with antibiotics on degradation of 
pulmonary junctional proteins upon S. aureus infection, we infected wt mice with a clinical S. 
aureus strain or the S. aureus Newman. One hour after infection with the incidence of first 
clinical symptoms, amitriptyline or methicillin or vancomycin or a combination of 
amitriptyline and either methicillin or vancomycin were injected. The injection of methicillin 
or vancomycin was repeated after 9 hrs. Control mice were left uninfected. The mice were 
sacrificed 12 hrs after infection and the left lungs were removed. Lung sections were stained 
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with anti-ZO1, anti-ZO2, anti-Occludin or anti-E-cadherin antibodies. The stainings were 
analysed by confocal fluorescence microscopy. The results showed that only treatment with 
amitriptyline alone or combining with antibiotics, but not treatment with methicillin or 
vancomycin alone, prevented breakdown of TJ proteins in vivo after infection of mice with S. 
aureus (Figure 4.6.3. A-D.). 
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Figure 4.6.3. The combination of amitriptyline and antibiotics inhibits degradation of 
pulmonary tight junctional proteins upon S. aureus infection 
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Wild-type mice were infected with a clinical S. aureus strain (A-D-1) or the S. aureus Newman strain 
(A-D-2). They were then left untreated; treated with an i.p. injection of amitriptyline (16 mg/kg) 1 h 
after infection; treated with either methicillin or vancomycin (both 100 mg/kg) 1 h and 9 hrs after 
infection; or treated with the combination of amitriptyline and methicillin or vancomycin. After 12 hrs 
infection, four mice per group were sacrificed and the left lungs were removed, fixed, dehydrated and 
embedded in paraffin for sectioning at a thickness of 6 µm. The lung sections were stained with 
Cy3-labeled anti-ZO1 (A), anti-ZO2 (B), anti-Occludin (C) or anti-E-cadherin (D) antibodies (scale 
bar is 10 µM, magnification, 40×). Representative fluorescence images from three independent 
experiments are shown. 
 
4.6.4. The combination of amitriptyline and antibiotics rescues mice form S. 
aureus-induced lung edema  
To determine the effect of the combination of amitriptyline with antibiotics on pulmonary 
edema upon S. aureus infection, we infected wt mice with a clinical S. aureus strain or the S. 
aureus Newman strain. One hour after infection, amitriptyline or methicillin or vancomycin 
or a combination of amitriptyline and either methicillin or vancomycin were injected. The 
injection of methicillin or vancomycin was repeated after 9 hrs. Control mice were left 
uninfected. The mice were sacrificed 12 hrs after infection and the left lungs were removed. 
Lung sections were stained with Hematoxylin-Eosin and analysed by confocal fluorescence 
microscopy. The results showed that only treatment with amitriptyline alone or combining 
with antibiotics, but not treatment with methicillin or vancomycin alone, prevented lung 
edema in vivo after infection of mice with S. aureus (Figure 4.6.4.A. and B.). 
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Figure 4.6.4. The combination of amitriptyline and antibiotics inhibits lung edema upon S. 
aureus infection 
 
Wild-type mice were infected with a clinical S. aureus strain (A) or the S. aureus Newman strain (B). 
They were then left untreated; treated with an i.p. injection of amitriptyline (16 mg/kg) 1 h after 
infection; treated with either methicillin or vancomycin (both 100 mg/kg) 1 h and 9 hrs after infection; 
or treated with the combination of amitriptyline and methicillin or vancomycin. After 12 hrs infection, 
four mice per group were sacrificed and the left lungs were removed, fixed, dehydrated and embedded 
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in paraffin for sectioning at a thickness of 6 µm. The lung sections were stained with 
Hematoxylin-Eosin (scale bar is 100 µM, magnification, 20×). Representative fluorescence images 
from three independent experiments are shown. 
 
4.7. The pharmacological treatment of lung edema and bacterial burden 
protects from lethality of S. aureus sepsis 
To investigate the link between bacterial burden and sepsis-induced lethality, we performed 
mortality experiments with untreated and pharmacologically treated wt and Asm-deficient 
mice after infecting them intravenously with 5×106 CFU S. aureus. Wt mice died between 26 
and 52 h after infection. Treatment of wt mice with amitriptyline delayed the death of the 
mice and the mice died between 50 and 85 h after infection. A very similar time course was 
observed for Asm-deficient mice that died between 50 and 80 h of infection. Treatment of wt 
mice with methicillin or vancomycin (1 and 9 h after infection and then twice daily) alone 
only rescued 50 % mice (11-day observation period). In contrast, the treatment of wt mice 
with a combination of amitriptyline and antibiotics rescued 100 % of infected wt mice, and no 
deaths were observed. Likewise, Asm-deficient mice under antibiotic intervention were also 
completely protected from sepsis-induced lethality (Figure 4.7.). 
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Figure 4.7. The pharmacological treatment of lung edema and bacterial burden protects from 
lethality of S. aureus sepsis  
 
Wild-type (wt) and Asm-deficient (Asm−/−) mice were infected intravenously with 5×106 CFU S. 
aureus. Mice were then left untreated or were pharmacologically treated with amitriptyline (Ami) (1 h 
after infection, then twice daily), methicillin (Methi), or vancomycin (Vanco) (1 and 9 h after infection 
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and then twice daily) or with a combination of amitriptyline and antibiotics. Survival was observed for 
up to 11 days. Data are shown in percent survival. Significance was determined by log-rank (Mantel–
Cox) test. 
 
In summary, these data indicate that the inhibition of lung edema in Asm-deficient or 
amitriptyline-treated mice together with a sufficient antibiotic treatment, which reduces the 
number of bacteria, is able to completely protect from lethality of S. aureus sepsis. 
 
4.8. Control studies 
4.8.1. Amitriptyline, Tiron or NAC has no effect on EOMA cells 
To eliminate the effect of the amitriptyline, Tiron or NAC on junctional proteins degradation 
in EOMA cells, we treated endothelial cells with 20 µM amitriptyline, 10 mM Tiron or 10 
mM NAC for 140 min and stained the cells with the antibodies against ZO1, ZO2, Occludin, 
and E-cadherin. We found that amitriptyline, Tiron or NAC alone is without effect on TJs 
degradation in EOMA cells (Figure 4.8.1.).     
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Figure 4.8.1. Effect of amitriptyline, Tiron or NAC on the distribution of ZO1, ZO2, Occludin 
and E-cadherin in EOMA cells 
 
EOMA cells were treated for 140 min with amitriptyline (20 µM), Tiron (10 mM) or NAC (10 mM). 
Immunoflourescence stainings were performed with antibodies against ZO1, ZO2, Occludin, or 
E-cadherin for determination of the degradation of these tight junction proteins. The presented pictures 
are representative of the results of at least three independent experiments (magnification, 40×). Scale 
bar is 25 µM. 
 
4.8.2. The drugs have no effect on lung parameters 
To eliminate the effect of the drugs on lung parameters in uninfected mice, amitriptyline or 
methicillin or vancomycin or a combination of amitriptyline and either methicillin or 
vancomycin were injected. The injection of methicillin or vancomycin was repeated after 8 
hrs. Control mice were left untreated. The mice were sacrificed 11 hrs after treatments. Lung 
sections were stained with Hematoxylin-Eosin (Figure 4.8.2.A.), anti-GR1 antibody (Figure 
4.8.2.B.) and anti-ZO1 (Figure 4.8.2.C.), anti-ZO2 (Figure 4.8.2.D.), anti-Occludin (Figure 
4.8.2.E.) or anti-E-cadherin (Figure 4.8.2.F.) antibodies. The stainings were analysed by 
confocal fluorescence microscopy. The studies confirmed that the drugs were without effect 
on lung parameters. 
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Figure 4.8.2. Effect of the drugs on lung parameters  
 
Wild-type mice were treated with an i.p. injection of amitriptyline (16 mg/kg), either methicillin or 
vancomycin (both 100 mg/kg) or with a combination of amitriptyline and Methicillin or vancomycin. 
Injection of the antibiotics was repeated after 8 hrs. After 11 hrs treatments, four mice per group were 
sacrificed and the left lungs were removed, fixed, dehydrated and embedded in paraffin for sectioning 
at a thickness of 6 µm. The lung sections were stained with Hematoxylin-Eosin (A) (scale bar is 100 
µM, magnification, 20×), Cy3-labeled anti-GR1 antibody (B) (scale bar is 50 µM, magnification, 
63×), or Cy3-labeled anti-ZO1 (C), anti-ZO2 (D), anti-Occludin (E) or anti-E-cadherin (F) antibodies 
(scale bar is 10 µM, magnification, 40×). Representative fluorescence images from three independent 
experiments are shown. 
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5. DISCUSSION 
5.1. Discussion of the Methods 
5.1.1. Determination of Asm activity in cell lysates 
Different methods are used to determine sphingomyelinase enzymatic activity, such as assays 
of pure enzyme and assays of cell extracts. In these assays the enzymatic activity of 
sphingomyelinase can be assayed by determining the conversion of sphingomyelin to 
ceramide and phosphorylcholine.  
 
For assaying purified sphingomyelinase, natural or synthetic sphingomyelin is prepared, pure 
or mixed with other lipids, in the form of extruded large unilamellar vesicles (LUVs) 
approximately 100 nm in diameter (Richards et al 1986). When LUVs are assayed with 
sphingomyelinase, ceramide production in the bilayers leads to vesicle aggregation, which in 
turn produces an increase in turbidity or light scattering in the suspension. Thus the reaction 
can be followed in real time just by measuring the increase in turbidity (absorbance at 500 
nm) or in light scattering (e.g. with a fluorometer with both the excitation and emission 
monochromators adjusted at 500nm). 
 
For assaying sphingomyelinase activity in cell lysates, sphingomyelin need to be labeled, 
radioactively, fluorescently or otherwise. In the present study, the enzymatic activity was 
measured as the degradation of radioactive [14C]-sphingomyelin to ceramide and 
[14C]-phosphorylcholine. Because [14C]-phosphorylcholine is soluble in water, it is easily 
separated from the substrate [14C]-sphingomyelin and ceramide, which remains in the organic 
phase following extraction. Sphingomyelin can serve as substrate for three forms of 
sphingomyelinases that manifest acid, neutral or basic pH optima for maximal enzyme 
activity (Hannun 1996). In the present study Asm activity was discriminated from the neutral 
or basic sphingomyelinase activity by performing the assay at pH 5.0. Because of the 
difficulty in bringing together the enzyme and substrate molecules in the presence of cell 
homogenates, a suitable detergent, such as Triton X-100 was used. It should be noted that, 
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apart from emulsifying the substrate, the detergents bind and modify the enzyme activity, thus 
detergent concentration and initial detergent:substrate ratio was kept constant for 
reproducibility of assays. Finally, it has been suggested that the Asm may be located in 
detergent-resistant/insoluble fractions; thus, for determination of Asm activity in whole-cell 
lysates, no centrifugation step was performed after lysis and sonication of the cells to prevent 
pelleting and loss of the Asm. 
 
5.1.2. Ceramide measurement by diacylglycerol (DAG) kinase assay 
The crucial role of ceramide in numerous cellular processes and particularly stress responses, 
has led to the necessity of developing rapid and quantitative assays for ceramide 
determination. In the literature, there are several methods reported for quantifying ceramide 
such as normal phase high performance liquid chromatography (HPLC) analysis after 
derivatization with a fluorescent tag (Couch et al 1997, Iwamori et al 1979, Previati et al 
1996, Yano et al 1998), evaporative lightscattering detection (McNabb et al 1999), high 
performance thin layer chromatography (HPTLC) analysis (Motta et al 1994), or using cells 
labeled with radioactive precursors   (Tepper et al 2000). Ceramide molecular species can 
be determined following hydrolysis and analysis of the liberated and derivatized sphingoid 
bases by means of HPLC (Nishimura et al 1985, Smith et al 1995) and fatty acids by means of 
GC/MS (Samuelsson et al 1969). New methods for quantitative analysis of ceramide 
molecular species have been developed and are based on HPLC or reversed phase HPLC 
(RP-HPLC) separation of their fluorescent analogs prepared after derivatization with anthroyl 
cyanide (Yano et al 1998), benzoyl chloride (Couch et al 1997), or benzoic anhydride  
(Iwamori et al 1979). Moreover, mass spectrometry methodologies have been developed for 
the detection of molecular species of ceramide (Couch et al 1997, Gu et al 1997, Kalhorn et al 
1999, Karlsson et al 1998, Liebisch et al 1999, Mano et al 1997, Watts et al 1999). However, 
most of these methods require long periods of processing and/or analysis. 
 
The DAG kinase assay is a widely used method for the rapid quantification of ceramide. The 
primary advantages of the DAG kinase assay are the measurement of total mass levels of 
ceramide; the use of crude lipid extracts in the assay; and the ability of process a large number 
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of samples in a rapid manner. DAG kinase activity was originally reported by Hokin and 
Hokin (Hokin et al 1959). The enzyme was validated as an analytical tool in measuring 
diglyceride levels by the demonstration of a linear relationship between the amount of 
diglyceride added to an in vitro assay and the amount of product (phosphatidic acid) formed. 
Ceramides share structural similarities with diglycerides, and Schneider and Kennedy 
reported that bacterial DAG kinase can utilize ceramide as a substrate with a Km nearly five 
times greater than that for diglyceride (Schneider et al 1973). Early attempts to use DAG 
kinase to quantify ceramide revealed a linear but non-quantitative relationship between 
substrate added and product formed. Further modification of the assay demonstrated that 
DAG kinase could also be used for quantitative conversion of ceramide to 
ceramide-1-phosphate over a range of 25 pmol to 2 nmol (Van Veldhoven et al 1995). These 
refinements have required special emphasis on the protocol of lipid extraction, purity of the 
reagents used for the preparation of the mixed micelles and on the development of high levels 
of recombinant DAG kinase. 
 
The nonpolar properties of ceramide require that it be extracted from cells in organic solvents. 
Thus, the cells are lysed in a solution containing chloroform and methanol. Acidification of 
lysates with hydrochloric acid helps extraction of shorter acyl chain ceramide-1-phosphates or 
hydroxylated ceramides, thus being important to gain optimal usage of the exogenously added 
ceramides or internal standards. In the DAG kinase reaction, it is critical that the substrate is 
in a soluble form for optimal conversion to product by the enzyme. Mixed micelles containing 
a non-ionic detergent, such as n-octyl-β-glucopyranoside, and a phosholipid, such as 
cardiolipin, are utilized for this purpose. Of particular importance is the level of ceramide 
conversion to ceramide-1-phosphate. For the DAG kinase assay to yield reliable quantitative 
results, the reaction must go to completion with total conversion of DAG and ceramide. 
Otherwise, the results become sensitive to the effects of the efficiency of the reaction (Km and 
Vmax consideration of the DAG kinase) and to possible ‘competition’ between DAG and 
ceramide as substrates. In the present study, an excess of enzyme and ATP was used which 
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allowed linear and quantitative conversion and was sufficient for the phosphorylation of 
cellular ceramides as well as exogenously added ceramide. 
 
5.1.3. Detection of lung edema by Evans Blue Dye 
Evans Blue dye is widely used to study in vitro cellular permeability (Patterson et al 1992) 
and in vivo vascular leakage (Ferrero 2004). Historically, the dye was introduced for its utility 
in blood volume determinations by the dye dilution technique (Gibson et al 1937). Eventually, 
because the very high affinity of the dye for albumin was discovered (Freedman et al 1969, 
Rawson 1943), it began to be used as a surrogate marker for serum albumin flux across the 
luminal barrier in many in vivo experimental situations. Although subsequent investigations 
have revealed that the dye-albumin conjugate is not covalent in nature (Le et al 1947), it 
continues to be used today in situations where use of radioactively labeled albumin is not 
feasible or for histological examinations of injured tissue (Finck et al 1989, Moitra et al 2007, 
Saria et al 1983). 
 
In the present study, pulmonary vascular permeability was estimated by using the Evans blue 
method. Evans blue dye, which strongly binds to albumin, is a well-known marker of protein 
extravasation in models of acute lung injury (Turnage et al 1995). A critical point to detect 
lung edema is to allow Evans blue dye to circulate for some time, which can ensure that 
albumin-bound Evans blue moves into the lung parenchyma through compromised vascular 
barrier in the lung. The major problem in detection of vascular leakage is the possibility of 
intravascular Evans blue dye residual. This would lead to an amplification of the optical 
density signal a false-positive result. To avoid this artifact, the lungs were perfused free of 
blood with phosphate-buffered saline via the pulmonary artery. Another crucial point is that 
total amount of dye should be calculated by means of a standard calibration curve. In the 
present study, results were expressed as µg/g of wet tissue. 
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5.1.4. Measurement of production of ROS by Electron Spin Resonance (ESR) 
ROS formation and signaling are of major importance and regulate a number of processes in 
physiological conditions, which has led to the necessity of developing specific and sensitive 
assays for ROS determination. In the literature, there are several methods reported to allow 
measurement of generation and accumulation of different ROS, particularly H2O2, O2.–, and 
NO, in cells and/or organisms, such as fluorescent ROS dye technologies (Chen et al 2010, 
Zielonka et al 2010), genetically encoded ROS reporters (Ostergaard et al 2001, 
Schwarzlander et al 2011), nanoparticle delivery systems (Koo et al 2007, Lee et al 2009), 
and nanotube ROS probes (Kim et al 2011, Leeuw et al 2007). However, there are two major 
problems associated with even the most recently developed ROS fluorescent probes that still 
persist: reversibility and reaction rate. 
 
ESR was first observed in Kazan State University by Soviet physicist Yevgeny Zavoisky in 
1944, and was developed independently at the same time by Brebis Bleaney at the University 
of Oxford. ESR spectroscopy is a technique for studying materials with unpaired electrons. 
The basic concepts of ESR are analogous to those of nuclear magnetic resonance (NMR), but 
it is electron spins that are excited instead of the spins of atomic nuclei. ESR is the most direct 
technique and an effective and unique way to detect free radicals in biological samples. ESR 
spectroscopy is particularly useful for studying organic radicals.  
 
Although unpaired electrons of species such as NO, ·OH, or O2·– are too low in concentration 
and short-lived to be directly detected by ESR in biological systems, this dilemma can be 
circumvented by ESR measurement of more stable secondary radical species formed by 
adding exogenous spin-traps—molecules that react with primary radical species to give 
longer-lasting radical adducts with characteristic ESR signatures that can accumulate to levels 
permitting detection (Blodig et al 1999, Chen 2008). As we known, the concentration of ROS 
is very low and this would lead to the difficulty for detecting by ESR. To avoid this artifact, 
enough cells need to be prepared. Finally, since superoxide dismutase (SOD) catalyzes the 
dismutation of superoxide radicals (O2.- + O2.- + 2H+ -- O2 + H2O2) (McCord et al 1969). In 
the present study, SOD-inhibited fraction of the signal was used to calibrate the system. 
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5.1.5. Asm-deficient animals 
To determine the crucial role of Asm in the present study, Asm-deficient mice were used. The 
Asm knock-out mouse was originally generated in the laboratory of Dr. E. Schuchman 
(Horinouchi et al 1995) and has been proven to be a valuable tool in investigating the role of 
Asm in different cellular processes. Unfortunately, a study from Nix and Stoffel (2000) 
reported marked biochemical alterations and membrane dysfunction in cells derived from 
their line of Asm knock-out mice such as: increase of sphingomyelin and gycosphingolipids 
in the plasma membrane of hepatocytes, reduction of caveolin levels in embryonic fibroblasts, 
reduced signalling through tyrosine kinases in T lymphocytes, lymphopenia, the absence of 
proliferation of T cells in response to anti-CD3, reduced expression of the anti-apoptotic 
adapter FLIP, and a paradoxical increase in apoptosis of anti-CD3 pre-treated splenocytes 
upon activation of CD95 (Nix et al 2000). Therefore, the authors concluded that the 
previously reported apoptotic abnormalities in Asm-deficient cells and tissues  (Cifone et al 
1995, Lin et al 2000, Morita et al 2000, Pena et al 2000, Perez et al 1997, Santana et al 1996, 
Zundel et al 1998, Zundel et al 2000) did not result merely from Asm deficiency, but rather 
were impacted by disruption of membrane microdomains in response to altered sphingolipid 
metabolism (Nix et al 2000). 
 
However, Lozano and co-workers pointed out that the phenotype of the Asm-deficient mouse 
line used in the study of Nix and Stoffel was different from the mouse line generated in the 
laboratory of Dr. Schuchman, which displayed, up to a certain age (12-16 weeks), only a 
minimal increase in sphingomyelin content, unchanged levels of caveolin-1, normal 
MAP-kinase signalling and tyrosine phosphorylation patterns, no lymphopenia, normal T 
cells proliferation and no decrease in FLIP levels (Lozano et al 2001). Furthermore, the life 
expectancy of around 9-10 months (Pena et al 2000, Santana et al 1996) was in contrast with 
that of the mice generated by Stoffel and co-workers, who reported that the life span of their 
Asm-deficient mice was maximally 4 months, with mice succumbing to advanced 
Niemann-Pick disease type A(Otterbach et al 1995). The mice used in the present study show 
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the earliest clinical manifestation of Niemann-Pick disease type A between 12-16 weeks of 
age; therefore, all the Asm-deficient mice involving in our experiments were carried out with 
animals younger than 10 weeks of age, before any biochemical, histological or clinical 
manifestations of Niemann-Pick disease type A were apparent. This excluded that the effects 
observed in the Asm-deficient cells were due to altered cellular processes (as described 
above) but instead, were completely dependent on the lack of Asm. 
 
5.2. Discussion of the Results 
5.2.1. Role of the Asm/ceramide system in redox signaling 
Our findings indicate that infecting endothelial cells with S. aureus activates Asm and thereby 
triggers the release of ceramide. Asm leads to the production of ROS by endothelial cells. 
Asm plays a critical role in S. aureus-triggered ROS release. S. aureus induces ROS 
accumulation in endothelial cells. These events were all absent in amitriptyline-treated mice 
that have a reduced Asm activity or in mice lacking the Asm genetically. Consistently, 
Reinehr and co-workers demonstrated that inhibiting Asm blocks the release of ROS, a 
finding suggesting that ROS functions downstream of Asm in hepatocytes (Reinehr et al 
2006). Similarly, inhibiting Asm attenuates the ceramide and ROS production induced by 
histone deacetylase/perifosin (Rahmani et al 2005), fenretinide (Lovat et al 2004), sodium 
nitroprusside (Sanvicens et al 2006), or P. aeruginosa (Manago et al 2015, Zhang et al 2007, 
Zhang et al 2008). Taken together, these data confirmed the notion that Asm activation and 
ceramide production are upstream signals of ROS production. 
 
NADPH oxidases (Nox), which are localized to various cellular membranes, are classically 
known as important ROS producers (Geiszt et al 2000, Lambeth 2004, Suh et al 1999). 
Ceramide induces the activation of ROS-generating enzymes, including NADPH oxidase, 
xanthine oxidase, NO synthase, and the mitochondrial respiratory chain (Corda et al 2001, 
Lecour et al 2006). In particular, ceramide has been shown to activate NADPH oxidase and to 
increase the production of ROS in a variety of mammalian cells, including human aortic 
smooth muscle cells (Bhunia et al 1997), endothelial cells (Zhang et al 2007), macrophages 
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(Zhang et al 2008) and erythrocytes (LaRocca et al 2014). The precise mechanism that how 
ceramide activates NADPH oxidase is not well understood. Because many stimuli activate 
NADPH oxidase by translocation and aggregation, it has been proposed that ceramide 
mediates the fusion of small raft domains to ceramide-enriched membrane platforms, which 
facilitate the aggregation of subunits of NADPH oxidase and enhances interactions between 
subunits of NADPH oxidase, thereby stimulating the production of ROS (Figure 5.2.1.)   
(Boini et al 2010, Jin et al 2008, Li et al 2007, Zhang et al 2006). Yi and colleagues 
demonstrated that ceramide in platforms may also directly enhance NADPH oxidase activity 
by activating small G protein Rac1/2 by activation of guanine nucleotide exchange factors 
(GEFs) such as Vav2 (Figure 5.2.1.)  (Li et al 2007, Yi et al 2007). 
 
 
Figure 5.2.1. A hypothetic model showing lipid rafts (LRs) and LRs clustering to form a 
redox signaling platform 
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Under resting condition, individual LRs with attached receptors are present in the membrane 
of ECs (panel for resting cells). These individual LRs are dynamic microdomains and carry 
several membrane-bound or attached proteins or enzymes such as G-proteins, protein kinases, 
or the subunits of NADPH oxidase gp91phox and p47phox. When ligands or agonists bind to 
their receptors on individual LRs, the clustering is activated to form a number of LR 
macrodomains or platforms with aggregation or recruitment of receptors, NADPH oxidase 
subunits, and other proteins such as Rac GTPase. Clustering of these proteins and enzymes 
leads to activation of NADPH oxidase and production of O2.-, which results in a prominent 
amplification of the transmembrane signal (panel for stimulated cells) (Li et al 2007). 
 
 
5.2.2. Role of ROS in Asm activation 
Our findings demonstrated that pretreating endothelial cells with the antioxidants 
N-acetylcysteine (NAC) and Tiron substantially inhibited Asm activation and the signaling 
events downstream of Asm activation, such as junctional proteins degradation induced by 
systemic S. aureus infection, thus indicating that ROS release is required for Asm activation. 
Moreover, several recent studies have indicated that the generation of ROS may be involved 
in the activation of Asm in response to various stimuli (Charruyer et al 2005, Dumitru et al 
2006, Scheel-Toellner et al 2004), which seems to conflict with the above conclusion that 
Asm activation results in ROS production. This conundrum is discussed below and an 
amplifying concept is presented. 
 
Scheel-Toellner and colleagues demonstrated that Asm activation, ceramide generation, and 
CD95 clustering play a crucial role in the spontaneous apoptosis of neutrophils; apoptosis was 
substantially delayed in Asm-deficient mice (Scheel-Toellner et al 2004). These events were 
pretreated by antioxidants indicating the dependence of the Asm on ROS. In accordance, 
pretreatment with the antioxidant pyrrolidine dithiocarbamate (PDTC) abolished Asm 
activation by ultraviolet (UV)-C light in U937 cells, a finding suggesting that ROS functions 
downstream of Asm (Charruyer et al 2005).  
 
In addition, Dumitru and colleagues also demonstrated the involvement of ROS in 
TNF-related apoptosis-inducing ligand (TRAIL)-induced activation of Asm and apoptosis 
(Dumitru et al 2006). Stimulation with TRAIL/DR5 led to activation of Asm and the 
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subsequent formation of ceramide-enriched membrane platforms, DR5 clustering, and 
consequent apoptosis. Pretreatment with antioxidants NAC and Tiron substantially inhibited 
TRAIL-induced Asm activation, ceramide/DR5 clustering, and apoptosis, demonstrating that 
ROS play a crucial role in TRAIL-induced Asm/ceramic activation (Dumitru et al 2006). 
Finally, studies investigating the cellular effects of Cu2+ showed that Cu2+ also promotes the 
ROS-dependent activation of Asm and leads to the death of hepatocytes (Lang et al 2007). It 
was shown that the accumulation of Cu2+, as occurred in Wilson disease, activates Asm in 
hepatocytes and triggers the release of ceramide in these cells. This process leads to 
Cu2+-induced hepatocyte death, which can be prevented by a deficiency in Asm (Lang et al 
2007). 
 
In summary, these studies demonstrate that Asm activity is regulated by ROS upon systemic 
S. aureus infection, but the enzyme also stimulates ROS release. Therefore, we proposed a 
positive feed-back loop and a vicious cycle of–induced Asm activation and ROS release. In 
this amplification model, initial activation of Asm results in ROS production, which further 
enhance activation of Asm thus forms a feed-forward loop for ROS production. This finding 
is similar to the results of previous studies showing a positive feedback loop between the Asm 
and ROS after infection of macrophages with P. aeruginasa (Zhang et al 2008). 
 
5.2.3. Role of the Asm/ceramide system and ROS for lung edema induced by systemic S. 
aureus infection 
The results of the present study demonstrate that genetic deficiency or pharmacologic 
inhibition of the Asm/ceramide system in mice protects against lung edema induced by 
systemic S. aureus infection. The Asm/ceramide system triggered the formation of ROS, 
resulting in degradation of tight junction proteins and neutrophil trafficking, followed by lung 
edema. Pretreatment of mice or treatment of already infected mice with amitriptyline, a potent 
functional inhibitor of Asm, both protected mice from lung edem caused by systemic S. 
aureus infection. All the data presented above indicate that Asm/ceramide is a novel key 
molecule for the induction of lung edema by systemic S. aureus infection. Furthermore, 
pretreatment of mice with the antioxidants N-acetylcysteine (NAC) and Tiron substantially 
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inhibited the events downstream of Asm activation, such as junctional proteins degradation, 
neutrophil trafficking and lung edema, thus indicating that ROS release is also required for 
lung edema induced by systemic S. aureus infection.  
 
It has been speculated that membrane rafts (MRs) and ROS may constitute an amplification 
system of redox signals and ceramide signaling cell membranes, which insures the efficiency 
of signal transduction (Li et al 2013a). The formation of such feed forward amplifying loop 
for MR redox and ceramide signaling may also be responsible for the temporospatial 
regulation of a complex signalosome that precisely and efficiently control cell function. If the 
activity of this regulatory loop is excessively enhanced, excessive production of both ROS 
and ceramide may result in the progress and development of different diseases or pathological 
processes (Li et al 2013a). 
 
With respect to the role of these domains for the regulation of vascular endothelial functions, 
it has been described by numerous studies. Zhang and colleagues demonstrated that 
transfection of Asm siRNA markedly attenuated CD95 ligand in isolated small bovine 
coronary arteries, and induced inhibition of endothelium-dependent vasorelaxation (a 
response to bradykinin) by 60 % (Zhang et al 2007). The results suggest that Asm, the release 
of ceramide, and MR-derived ceramide-enriched membrane platforms are involved in the 
activation of NADPH oxidase in response to cytokines in coronary ECs, consequently leading 
to endothelial dysfunction (Jin et al 2007, Zhang et al 2006, Zhang et al 2007). 
 
Moreover, the MR redox signaling platform associated with NADPH oxidase has been 
demonstrated to be responsible for endothelial dysfunction induced by various stimuli such as 
death receptor activation, homocysteine, cytokines, or adipokines (Jin et al 2008, Xia et al 
2011, Zhang et al 2006). As a commonly used functional study, endothelium-dependent 
vasodilation (EDVD) response in isolated perfused arteries was tested. It was found that 
various stimulations which led to the formation of MR redox signaling platforms such as 
CD95 ligand, endostatin, homocysteine, and visfatin all led to impairment of EDVD. This 
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impairment was homeostatically recovered by NADPH oxidase inhibition using apocynin, or 
Asm siRNA, suggesting that MR redox signaling platforms with NADPH oxidase participate 
in the impairment of endothelial function (Jin et al 2008, Zhang et al 2007).  
 
In addition, platelet-activating factor (PAF), lipopolysaccharide (LPS) or acid instillation 
treatment induces Asm-dependent production of ceramide and results in pulmonary edema 
and has a key role in ALI. Agents that interfere with PAF-induced ceramide release, such as 
steroids or the xanthogenate D609, attenuate pulmonary edema formation induced by PAF, 
endotoxin or acid instillation. These results identify Asm and ceramide as possible therapeutic 
targets in acute lung injury (Goggel et al 2004). 
 
During sepsis, ALI results from activation of innate immune cells and endothelial cells by 
endotoxins, leading to systemic inflammation through pro-inflammatory cytokine 
overproduction, oxidative stress, and intracellular Ca2+ overload. Recent data by Gandhirajan 
and co-workers indicate that ROS-driven Ca2+ signaling promotes vascular barrier 
dysfunction and induce pulmonary edema (Gandhirajan et al 2013). 
 
All the experiments confirmed the notion that feed forward amplifying loop of Asm/ceramic 
and ROS is involved in systemic S. aureus–induced pulmonary edema. 
 
5.2.4. Role of junctional proteins degradation for lung edema induced by systemic S. 
aureus infection  
As we known endothelial barrier dysfunction occurs during stimulation by inflammatory 
agents, pathogens, activated blood cells, or disease states. The pathophysiology is 
characterized by excessive flux of plasma across the exchange micro-vessel wall into the 
surrounding tissues. Traditionally, compromised endothelial cell–cell junctional integrity is 
considered to account for the leak response. 
 
A principal hallmark of lung edema is degradation of junctional proteins, which induces the 
disruption of endothelial cell barrier, followed by excessive flux, neutrophil trafficking and 
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consequently lung edema. Clinicians have long recognized the problem of vascular leak but 
had no tools to reverse it. 
 
Out data presented here indicate that systemic S. aureus infection induces lung edema via 
degradation of junctional proteins. Genetic deficiency of the Asm/ceramide system in mice 
protects against junctional proteins degradation and reduces lung edema induced by systemic 
S. aureus infection.  Furthermore, pre-treatment of the mice or treatment of already infected 
mice with amitriptyline both protected mice from junctional proteins degradation and reduces 
lung edema. Likewise, pretreatment of mice with the antioxidants N-acetylcysteine (NAC) 
and Tiron substantially inhibited junctional proteins degradation and reduces lung edema.  
 
The experiments further suggest, on one hand, the feed forward amplifying loop for 
Asm/ceramide and ROS is required for degradation of junctional proteins induced by 
systemic S. aureus infection; on the other hand, junctional proteins degradation is responsible 
for lung edema induced by systemic S. aureus infection. This concept is consistent with 
findings that superoxide can directly down-regulate TJ proteins and indirectly activate matrix 
metalloproteinases (MMPs) that contribute to disrupt the integrity of endothelial cell layers 
(Gu et al 2011). Moreover, superoxide directly activates several inflammatory cytokines, 
which in turn activate MMPs (Abdul-Muneer et al 2015, Gu et al 2011, Rochfort et al 2014). 
Furthermore, in some pathological conditions, ROS induce the degradation of tight junctional 
proteins, following by vascular leakage and neutrophil trafficking with consequent pulmonary 
edema (Catanzaro et al 2015, Naik et al 2014). 
 
All the data presented above indicate that antidepressant amitriptyline and antioxidants 
N-acetylcysteine (NAC) and Tiron might be very useful for future therapies for lung edema 
induced by degradation of junctional proteins. At the same time, the development of agents or 
mediators that reinforce intercellular junctional proteins should be a goal of drug research. 
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5.2.5. Role of neutrophil recruitment for lung edema induced by systemic S. aureus 
infection  
Lung edema, endothelial and epithelial injury are accompanied by an influx of neutrophils 
into the interstitium and broncheoalveolar space. Neutrophils are considered to play a key role 
in the progression of ALI/ARDS since activation and transmigration of neutrophils is a 
hallmark event in the progression of ALI/ARDS (Abraham 2003).  
 
The importance of neutrophils in ALI/ARDS is affirmed by clinical data and animal models. 
In patients with ARDS, the concentration of neutrophils in the bronchoalveolar lavage (BAL) 
fluid correlates with severity of ARDS and outcome (Matthay et al 1984, Parsons et al 1985, 
Steinberg et al 1994). Furthermore, depletion of neutrophil in mice reduces the severity of 
lung injury (Abraham et al 2000). Interestingly, blocking interleukin-8 (IL-8), a major 
chemoattractant for neutrophils, protects rabbits from acid aspiration-induced lung injury 
(Folkesson et al 1995). Further to emigration, neutrophils are irreplaceable in bacterial 
clearance, much of which is mediated by phagocytosis and intracellular bacterial killing 
(Soehnlein 2009). Even so, ALI/ARDS can occur in children and adults with neutropenia 
(Laufe et al 1986, Ognibene et al 1986, Sivan et al 1990), which indicates that 
neutrophil-independent mechanisms alone allow for development of ALI/ARDS under 
specific conditions. Despite that, a multitude of experimental and clinical data point at the 
causative role of neutrophils in lung injury. 
 
The present study indicates that neutrophil trafficking plays a key role in lung edema induced 
by systemic S. aureus infection. Genetic deficiency of the Asm/ceramide system in mice 
reduces neutrophils trafficking, consequently protects the mice against lung edema induced by 
systemic S. aureus infection.  Furthermore, pre-treatment of the mice or treatment of already 
infected mice with amitriptyline both protected mice from neutrophil trafficking and reduces 
lung edema. Furthermore, pretreatment of mice with the antioxidants N-acetylcysteine (NAC) 
and Tiron substantially inhibited neutrophils trafficking and reduces lung edema.  
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The experiments further suggest, on one hand, the feed forward amplifying loop for 
Asm/ceramide and ROS is required for neutrophil trafficking induced by systemic S. aureus 
infection; on the other hand, neutrophil trafficking is involved in lung edema induced by 
systemic S. aureus infection. Consistently, it has recently been shown that recruitment of 
neutrophils is a key event in development of ALI, linking to plasma leakage and deterioration 
of oxygenation (Grommes et al 2011, Ware et al 2000). LPS inhalation mimics human 
Gram-negative ALI, inducing neutrophil recruitment, pulmonary edema and finally 
impairment of gas exchange (Matute-Bello et al 2008). Moreover, the importance of 
neutrophils in ALI is supported by studies where lung injury is abolished or reversed by 
depletion of neutrophils (Looney et al 2006, Soehnlein et al 2008). 
 
Hence, antidepressant amitriptyline and antioxidants N-acetylcysteine (NAC) and Tiron might 
be very useful for future therapies for lung edema induced by neutrophils trafficking. At the 
same time, the development of agents or mediators that decrease neutrophils recruitment 
should be a goal of drug research.  
 
5.2.6. Clinical significance of combination of amitriptyline and antibiotic 
S. aureus is a leading cause of septic infections, and S. aureus–induced sepsis is one of the 
most serious infections acquired in hospitals or in the community. However, even with the use 
of appropriate antibiotics, fatal lung edema often develops (Cortes Garcia et al 2012, Moore et 
al 2011, Moore et al 2012). Despite many clinical trials, no FDA-approved drug is available 
for use in sepsis, a lack that underscores the importance of future sepsis research. 
Interestingly, our studies with wt and Asm-deficient mice seem to mimic the situation in 
hospitals showing a high lethality in septic S. aureus infections even if adequately treated 
with antibiotics (Cortes Garcia et al 2012, Moore et al 2011, Moore et al 2012). 
 
Our findings demonstrate that treating mice with amitriptyline 1 or 2 h after infection reduces 
S. aureus–induced pulmonary edema and also inhibits myeloid cell trafficking and the 
degradation of junctional proteins. The reduced capacity of mice treated with amitriptyline or 
Asm-deficient mice to kill S. aureus is consistent with the previous notion that myeloid cells 
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lacking Asm are unable to cluster and activate NADPH oxidases resulting in a defect of the 
production of superoxide and a reduced killing of pathogens. Finally, amitriptyline-treated or 
Asm-deficient mice died by the inability to eliminate the bacteria. In contrast, antibiotics kill 
the bacteria, but did not reduce lung edema. Thus, the combination of amitriptyline and 
antibiotics combines the advantages of inhibiting lung edema and eliminating systemic 
bacteria, protecting mice from lethality. 
 
It is very interesting that Goggel and co-workers demonstrate that steroids or the 
xanthogenate D609, which can interfere with PAF-induced ceramide synthesis, inhibit 
pulmonary edema formation induced by platelet-activating factor (PAF), lipopolysaccharide 
(LPS) or acid instillation (Goggel et al 2004). These results indicate that Asm/ceramide 
signaling plays an important role in pulmonary edema induced by PAF instillation. 
 
However, the molecular mechanisms how the Asm/ceramide system induces lung edema is 
largely unknown. According to previous studies, eNOS/eNO might be involved in this role. It 
has been reported that pharmacological inhibition of the Asm pathway with imipramine, 
D609 or dexamethasone blocks the PAF-induced increase of caveolin-1 and eNOS in 
caveolae, and the decreases in eNO production and edema formation in rat lung (Yang et al 
2010).  These results suggest that inhibition of eNOS/eNO signaling decreases PAF-induced 
lung edema. 
 
More recently, Samapati and colleagues indicate PAF increases lung edema and endothelial 
Ca2+. This response is abrogated by inhibitors of Asm or in Asm-deficient mice, and 
replicates by lung perfusion with exogenous Asm or C2-ceramide. Further experiments 
demonstrate that PAF increases the caveolar abundance of TRPC6 channels via Asm 
activation, subsequently induces increases in lung endothelial Ca2+, vascular filtration 
coefficient, and edema formation , which were attenuated by the TRPC inhibitor SKF96365 
and in TRPC6-deficient mice, whereas direct activation of TRPC6 replicated the Ca2+ and 
edema response to PAF. The exogenous NO donor PapaNONOate or the cyclic guanosine 
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3′,5′-monophosphate analog 8Br-cGMP blocked the endothelial Ca2+ and permeability 
response to PAF (Samapati et al 2012).  
 
According to our data, the Asm/ceramide system induces lung edema by junctional proteins 
degradation and neutrophil trafficking, which is a novel viewpoint to explain how the 
Asm/ceramide system induces lung edema upon systemic S. aureus infection. 
 
5.2.7. Possible additional roles of Asm as activator of ADAM 10 
S. aureus expresses multiple toxins, such as alpha-toxin, Panton-Valentine leukocidin, and 
enterotoxin B and A, which cause membrane damage, infiltration of myeloid cells and 
macrophages, cytokine production, and increased vascular permeability resulting in severe 
pulmonary edema and lung injury (Bhakdi et al 1984, Diep et al 2010, Mattix et al 1995, 
Menoret et al 2012).  
 
 Pore-forming cytotoxins (PFTs) are a family of bacterial virulence factors that cause 
eukaryotic cell injury and death (Gonzalez et al 2008). S. aureus encodes multiple PFTs, the 
best-studied being α-hemolysin (Hla), which is expressed by almost all strains (Tomita et al 
1997). Hla is involved in the pathogenesis of skin infections, pneumonia, corneal infection 
and toxic shock syndrome (Brosnahan et al 2009, Bubeck Wardenburg et al 2007a, Bubeck 
Wardenburg et al 2007b, Kennedy et al 2010, O'Callaghan et al 1997), including those caused 
by MRSA.  
 
Both of the S. aureus strains used in our study produce several hemolysins. It is possible that 
S. aureus toxins mediate the activation of the Asm observed in the present study after 
infection of endothelial cells with S. aureus. However, at present, it is unknown whether 
purified alpha-toxin activates the Asm in human and mouse monocytic cells. Recently, it was 
reported that the binding of Hla to its eukaryotic receptor A-disintegrin and metalloprotease 
10 (ADAM10) leads to the up-regulation of ADAM10 activity, which is required for 
Hla-induced cytotoxicity (Inoshima et al 2011, Powers et al 2012, Wilke et al 2010). 
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Increased ADAM10 activity in epithelial and endothelial cells and following signaling 
cascades disrupts the cell barrier function, and this disruption contributes to the pathogenesis 
of lethal lung edema. However, it is unknown whether the Asm and ADAM10 function in the 
same signaling cascade or are independent pathways that are both required for the cellular 
effects of alpha-toxin.  
 
5.2.8. Possible additional roles of Asm as activator of the Nalp3 inflammasome 
Microorganisms that invade the cytosol can be recognized by cytoplasmatic 
pattern-recognition receptors (PRRs), most notably the nucleotide-binding and 
oligomerization domain, leucine-rich repeat (also known as NOD-like receptors, both 
abbreviated to NLR) (Kawai et al 2010, Schroder et al 2010). NLRs, which detect microbial 
components in the cytosol and trigger the assembly of large caspase-1-activating complexes 
termed inflammasomes, are further subcategorized based on differences in the N-terminal 
domains (Schroder et al 2010, Stutz et al 2009). Amongst the various inflammasomes, the 
NALP3 inflammasome is particularly qualified to response to various activators, leading to 
caspase activation. NLRP3 inflammasome activation induces caspase-1 activation, which 
causes the processing of the pro-inflammatory cytokines IL-1β and IL-18 and triggers the 
inflammatory stress (Schroder et al 2010, Stutz et al 2009). IL-1 β is an early cytokine in ALI 
patients and induces alveolar permeability and causes production of other cytokines such as 
IL-6 and TNF-a (Ganter et al 2008). 
 
S. aureus is a potent activator of the inflammasome in macrophages resulting in upregulation 
of caspase-1 upon its interaction with Asc and NALP3 (Mariathasan et al 2006). Moreover, 
α-hemolysin activates the NALP3-inflammasome during S. aureus pneumonia, inducing 
necrotic pulmonary injury. Moreover, Nalp3-/- mice have less-severe pneumonia (Kebaier et 
al 2012). In addition, purified α-hemolysin activates the NALP3-inflammasome, ultimately 
leading to the secretion of the pro-inflammatory cytokines IL-1β and IL-18 and the resultant 
tissue necrosis and inflammation (Craven et al 2009). 
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Recently, it was reported that the inflammasome protein complex activates caspase-1 to 
promote the processing and secretion of IL-1β, which is responsible for alveolar epithelial 
permeability. In addition, it is shown that inflammasome inhibition blocks hyperoxia-induced 
alveolar permeability and cytokine production (Kolliputi et al 2010). Later, Kolliputi and 
colleagues further reveal that ceramide causes NALP3-inflammasome activation, induction of 
caspase-1, IL-1β cleavage, release of pro-inflammatory cytokines, and ultimately alveolar 
epithelial permeability. Short-hairpin RNA silencing of NALP3-inflammasome components 
abrogated ceramide-induced secretion of pro-inflammatory cytokines and abolished 
ceramide-induced alveolar epithelial permeability in in vitro (Kolliputi et al 2012). However, 
the role of inflammasome in relation to S. aureus-induced Asm/ceramide activation and 
inflammatory cytokine production leading to endothelial permeability remains unknown.  
 
5.2.9. Significances and perspectives 
In the present study, we demonstrated that the combination of amitriptyline and antibiotics 
effectively protects mice from lung edema and bacteremia during sepsis. Amitriptyline is a 
well-known antidepressant that has been widely used in clinical practice for more than 50 
years and is associated with only mild adverse effects at therapeutic doses. Thus, the major 
significance of the research work in this dissertation is to indicate that inhibition of the 
Asm/ceramide system in combination with antibiotics could be a novel approach to treat 
severe systemic and often lethal infections and to inhibit lung injury in patients with incipient 
sepsis. The results presented in this dissertation increases our understanding of the signaling 
mechanisms responsible for the acute ROS response in endothelial cells during host-pathogen 
interaction and link the function of Asm with ceramide redox signaling. The notion that Asm 
deficiency or antioxidants prevent S. aureus-induced Asm/ceramide activation, ROS release, 
junctional proteins degradation, neutrophil trafficking and lung edema, which may contribute 
to the understanding how systemic S. aureus infections induce lung edema. This may direct 
the development of new therapeutic strategy for treatment of this disease. 
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6. SUMMARY 
Pulmonary edema associated with increased vascular permeability is a severe complication of 
S. aureus–induced sepsis and an important cause of human pathology and death. Antibiotics 
alone are often insufficient to cure patients with S. aureus–induced sepsis. Although treatment 
with effective doses of bactericidal antibiotics indeed prevents the bacterial burden, 
antibiotics often fail to prevent fatal lung edema after septic infection with S. aureus. 
 
The present study investigated the role of the Asm/ceramide system in the development of 
lung edema caused by S. aureus. Furthermore, the present study identified signaling 
mechanisms responsible for lung edema caused by S. aureus. Most importantly, the present 
study identifies a novel approach to patients with S. aureus-induced sepsis with bactericidal 
antibiotics applied in combination with amitriptyline. The major findings are: 
 
 S. aureus rapidly activates Asm and induces ceramide release in the plasma 
membranes. 
 The Asm/ceramide system mediates S. aureus-induced ROS production. 
 The Asm/ceramide system and ROS form a positive feedback loop. 
 Asm and ceramide activation are crucial for S. aureus-induced lung edema. 
 ROS is essential for S. aureus-induced lung edema. 
 The Asm/ceramide system and ROS activation lead to junctional proteins 
degradation. 
 The Asm/ceramide system and ROS activation lead to neutrophil trafficking. 
 Both junctional proteins degradation and neutrophil trafficking contribute to lung 
edema induced by S. aureus infections. 
 Genetic deficiency or pharmacologic inhibition of the Asm/ceramide system in mice 
protects against lung edema induced by systemic S. aureus infection. 
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 Pretreating endothelial cells with the antioxidants N-acetylcysteine (NAC) or Tiron 
substantially inhibited Asm activation and the signaling events downstream of Asm 
activation. 
 The combination of antibiotics and amitriptyline reduced both pulmonary edema and 
bacteremia protecting mice from lethal sepsis and lung dysfunction. 
 
Therefore, the proposed signaling pathway is depicted as bellow: 
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